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Abstract 
Differentiation of distinct CD4+ T effector cell subsets is a key event for adaptive 
immune responses. Upon recognition of antigens, naïve CD4+ T cells differentiate into 
functionally distinct CD4+ effector T cell subsets, which control different types of 
adaptive immunity. The differentiation of CD4+ T effector cells is regulated by the 
BATF-containing AP-1 heterodimers and their associating proteins IRF4, BATF and 
IRF4 are induced by T cell receptor (TCR) and co-stimulatory signals and regulate 
expression of genes required for a broad spectrum of biological functions across diverse 
CD4+ effector T cell subsets. These transcription factors have been shown to be 
essential for lineage specification, metabolic activity, and survival of various CD4+ 
effector T cell subsets, including T helper 1 (Th1), Th2, Th9, Th17, follicular T helper 
(Tfh) and effector regulator T (eTreg) cells. In contrast to IRF4 and BATF, the role of 
the major BATF-heterodimeric partner, JunB, in CD4+ T cell differentiation is still not 
fully understood. In this thesis, I demonstrate that JunB promotes the survival of TCR-
stimulated CD4+ T cells under Th1-, Th2-, and Th17-polarizing conditions. Consistent 
with this, accumulation of antigen-primed JunB-deficient CD4+ T cells are dramatically 
impaired in mice immunized with complete Freund’s adjuvant (CFA), LPS, or papain. 
RNA-sequencing (RNA-seq) and chromatin immunoprecipitation sequencing (ChIP-
seq) analyses reveal that JunB directly regulates expression of various genes that are 
commonly induced in priming of naïve CD4+ T cells, including a pro-apoptotic gene 
Bcl2l11 (encoding Bim), and genes that are specifically induced in Th1, Th2, and Th17 
cells. Furthermore, JunB colocalizes with BATF and IRF4 at genomic regions for more 
than 70% of JunB direct responsive genes. Taken together, JunB, in collaboration with 
BATF and IRF4, serves a critical function in differentiation of diverse CD4+ T cells by 
controlling common and lineage-specific gene expression. 
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Chapter 1: General introduction 
 
Overview of Immune system 
Mammals live in an environment full of pathogens and have evolved two sophisticated 
immune systems to prevent infection: innate and adaptive immune systems. The innate 
immune system operates in a rapid and non- -specific way to provide the first line of 
defense. On the other hand, the adaptive immune system protects host in a pathogen-
specific manner. 
The first line of defense of innate immune system is tissues such as skin and 
mucosal membrane that create physical barriers impermeable for pathogens. In addition, 
lytic enzymes secreted by epithelial cells surrounding those barrier tissues can also help 
to remove microbes adhered to host surface tissues. The second responders are innate 
immune cells. These cells utilize their pattern-recognition receptors (PRRs) to sense 
pathogen-derived molecules such as lipoprotein, lipopolysaccharides (LPS), flagellin, 
and pathogen-derived DNA and RNA (1). Upon perceiving the presence of pathogen-
derived molecules, innate immune cells actively perform phagocytosis to engulf 
pathogens themselves or pathogen-derived substances. Engulfed substances are further 
digested by lytic enzymes within a specific organelle called phagosome. In addition to 
phagocytosis, innate immune cells secrete lytic enzymes or toxic substances into their 
surrounding environments and kill pathogens (2, 3). 
The main responders of adaptive immune systems are B cells and T cells. B cells 
produce soluble forms of immunoglobulins (antibodies) that directly bind to pathogen-
derived molecules (antigens). The binding of antibodies not only neutralizes the toxicity 
of antigens but also enhances phagocytosis of antigen by phagocytes. On the other hand, 
T cells utilize membrane-bound T cell receptors (TCRs) to recognize antigens. Instead 
of interacting with antigens themselves, TCRs interact with complexes of antigens and 
major histocompatibility complex (MHC) molecules (4).  
T cells are divided into two groups: CD4+ and CD8+ T cells, according to the types 
of coreceptor (CD4 or CD8) expressed on their surfaces. Upon antigen recognition, 
CD4+ T cells secrete various cytokines, which can regulate various immune cells. On 
the other hand, activated CD8+ T cells release cytotoxic substances to kill pathogen-
infected cells.  
Innate and adaptive immune systems are deeply intertwined. In the process of 
phagocytosis, pathogen-derived peptide antigens are bound with MHC molecules. The 
antigen:MHC complexes are subsequently presented on the surface of innate immune 
cells and exposed to T cells – a process is called antigen presentation. Naïve T cells 
activated by antigen presentation differentiate into effector T cells. A subset of effector 
T cells, follicular T helper cells, can help naïve B cell activation and germinal center 
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reactions. These adaptive immune responses reciprocally promote efficient activation 
of innate immune cells. This synergism between adaptive and innate immune cells is 
the basis in maintaining host health.  
 
Innate immune cells 
When pathogens break physical and chemical barriers formed by tissues, innate 
immune cells perform phagocytosis, digestion, and lysis of invading agents. Innate 
immune cells are a group of white blood cells, including basophils, neutrophils, 
eosinophils, dendritic cells, monocytes, macrophages, mast cells, and NK cells (Fig.1) 
(1). By utilizing their pattern recognize receptors (PRR), innate immune cells sense the 
presence of common pathogen-associated molecular patterns and execute pathogen 
clearance. The binding between PRR and pathogen molecules initiate a series of innate 
immune responses, including activation of complement molecules, phagocytosis, and 
secretion of inflammatory cytokines. In contrast, natural killer (NK) cells can sense 
alteration of surface molecule expression of pathogen-infected cells using various NK 
receptors and trigger apoptosis of the infected cells (Fig. 1) (3).  
Secreted PRRs, including Mannan-binding lectin (MBL), C-reactive protein 
(CRP), and serum amyloid protein (SAP) can activate complement system (3). MBL 
binds to mannose residue of bacterial cell surface and activates MBL-associated serine 
proteases, MASP-1, and MASP-2, which can trigger the formation of C3 convertase. 
Once the C3 convertase is activated, it leads a series of protein cleavage events and 
assembles of membrane attack complex (MAC). The MAC forms pores on the 
membrane and induce cell lysis of pathogens (Fig. 1) (5). Similarly, CRP and SAP 
respond to different types of bacterial surface components and lead the activation of C3 
convertase (3).  
Another innate effector mechanism is phagocytosis, by which innate immune cells 
engulf and digest pathogens with lytic enzymes. Asubset of innate immune cells, 
including macrophages, dendritic cells, monocytes and neutrophils, performs 
phagocytosis with high efficiency and is considered as phagocytes (Fig. 1) (6). The 
efficiency of phagocytosis could be further enhanced if pathogen-derived 
molecules:PRR complexes are co-bound with host-derived proteins such as 
complement molecules or antibodies. This group of protein is called opsonins, which 
helps phagocytosis (6).   
Phagocytosis is also an important step for processing and exposing pathogen-
derived peptide antigens – a process called antigen presentation. Because of their high 
efficiency in phagocytosis and antigen processing abilities, macrophages, dendritic cell, 
and B cells are called antigen presenting cells (APC) (Fig. 1) (1). During antigen 
presentation, pathogen-derived peptide antigens are firstly released into phagosomes 
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and fused with other organelles that are originated from endoplasmic reticulum. In these 
fused vesicles, peptide antigens are loaded into Major Histocompatibility Complex 
(MHC) proteins and transported to the plasma membrane. The exposed antigen:MHC 
complexes can interact with TCR of T cells and induce T cell differentiation. B cells 
can also present antigens and interact with T cells. In this way, B cells then respond to 
cytokines released by T cells and subsequently produce antibodies (Fig. 1). This 
reciprocal activation of B and T cells is called T-cell-dependent B cell response and is 
an indispensable process for antibody production (7).   
To summarize, innate immune cells are not only the actual executor in pathogen 
clearance but are also essential for activation of adaptive immune response. Antigen 
presentation performed by phagocytes serves as an important pivot in linking innate 
and adaptive immune systems (Fig. 1) (8). 
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Fig. 1. An overview of immune system and the integration between innate and 
adaptive immune cells. 
Innate immune cells are the first line of immune system. They perform phagocytosis 
and release cytotoxic substances to clear pathogens. Innate immune cells also secrete 
pattern recognition receptors to initiate the formation of membrane attack complexes 
(MAC) and cause lysis of bacteria. A subset of innate immune cells, natural killer cells, 
induces apoptosis of cells infected by intracellular pathogens such as virus. Innate 
immune cells specializing in phagocytosis are called phagocytes, including 
macrophages, dendritic cells, monocytes, and neutrophils. Those cells also dedicate to 
perform antigen presentation (Red arrows and rectangle) to load pathogen-derived 
peptide antigens with major histocompatibility complex (MHC) and activate both CD4+ 
and CD8+ T cells. In addition to innate immune cells, B cells could also present antigens 
to T cells. Antigen presentation of B cells to CD4+ T cells also activates B cells itself 
and produce antibodies. Activated CD4+ T and B cells secrete cytokines and antibodies, 
respectively, which further promotes antigen clearance of innate immune cells (Blue 
arrows).  
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Adaptive immune cells 
The main players in adaptive immune system, B and T cells, need to undergo primary 
and secondary differentiation to have antigen-removal functions. In the primary 
differentiation, precursor B and T cells become mature naïve B and T cells in bone 
marrow and thymus, respectively (Fig. 2A). Naive B and T cell then enter circulatory 
system and travel to lymphatic organs such as spleens and lymph nodes, where naïve T 
cells receive antigen signals from antigen presenting cells (APCs) and undergo the 
secondary differentiation into effector T cells. Naïve B cells are activated by antigen 
directly with help from CD4+ effector T cells. Both effector B and effector T cells can 
reenter circulatory system and migrate toward peripheral tissues under inflammatory 
conditions (Fig. 2B) (4).  
B and T cells express a specialized subset of proteins to recognize a specific 
portion of target antigens during pathogen clearance. Naïve B cells express membrane-
bound immunoglobulins to interact with antigens themselves, whereas effector B cells 
produce soluble forms of immunoglobulins (antibodies) to directly bind to antigen-
bearing pathogens. On the other hand, both naïve and effector T cells utilize membrane-
bound T cell receptors (TCRs) for recognizing antigens. Instead of interacting with 
antigens themselves, TCRs interact with complexes of antigens and major 
histocompatibility complex (MHC) molecules expressed on APC (4). 
T cells are further divided into CD4+ T and CD8+ T cells, depending on which 
types of co-receptors (CD4 or CD8) of TCRs are expressed. CD4+ T cells utilize CD4 
and TCRs to interact with specific antigens presented with MHC class II proteins on a 
variety of APC. Upon antigen stimulation, effector CD4+ T cells secrete small soluble 
proteins – cytokines. Cytokines largely modulate behaviors of both innate immune cells 
and B cells. On the other hand, CD8+ T cells utilize CD8 and TCRs to bind to specific 
antigens presented with MHC class I proteins on pathogen-infected cells or tumor cells 
and release cytotoxic substances to kill target cells. CD8+ T cells also release cytokines 
to induce apoptosis in cells infected by pathogens (4).  
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Fig. 2. The development of B and T cells.  
(A) The common lymphoid progenitors (CLP) differentiate to naïve B cells and early 
thymocyte progenitor (ETP) in bone marrow. ETP then migrate to thymus and 
differentiate into naïve T cells. (B) Both naïve B and T cells enter circulatory system 
and move to lymphatic organs such as spleen and lymph nodes, where T cells are 
activated by antigen presenting cells (APC) and become effector T cells. B cells are 
activated either by antigens directly with help from T cells and become effector B cells. 
Effector B and T cells can travel to tissues under inflammation. (A-B) Red dashed lines 
indicate the cell migration is through circulatory system. 
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CD4+ T cells: integrator of innate and immune system 
CD4+ T cells orchestrate the immune system and integrate innate and adaptive immune 
responses against pathogen infection in a systematic manner.by releasing different types 
of cytokines that modulate behaviors of a variety of cells (3, 4). Dependent on the ability 
causing inflammation, cytokines are divided into proinflammatory and anti-
inflammatory cytokines. Proinflammatory cytokines such as IL-6 and IFN-γ enhance 
proliferation, phagocytosis, production of free radicals and apoptosis of innate immune 
cells. IFN-γ also promotes antigen presentation of APC by upregulating expression of 
MHC molecules (9). In contrast, anti-inflammatory cytokines such as IL-10 and TGF-
β inhibit the growth of innate immune cells by induces expression of inhibitor proteins 
of cyclin-dependent kinases (CDK) activities (Fig. 3) (10, 11).  
Cytokines secreted by CD4+ T cells also help B cells to switch the production of 
immunoglobulins from membrane-bound immunoglobulin M (IgM) and IgD to various 
soluble forms of antibodies, including IgA, IgG, and IgE – a process called class switch 
(12). Class switch changes the constant regions of antibody without affecting its 
specificity against antigens, enabling B cells to produce antibodies interacting with 
different effector molecules. For example, binding between antigens and IgG activates 
complement molecules, similar as the mechanism of mannose binding proteins, lead 
the formation of membrane attack complex on bacteria cell wall. Each antibody class 
exhibits unique distribution to various host tissues (Fig. 3)(12).  
Although CD4+ effector T cells only have a little effect on the generation of CD8+ 
effector T cells, cytokines released by CD4+ effector T cells such as IL-2 are required 
for long-term survival and proliferation of a subset of CD8+ T cells – memory CD8+ T 
cells (Fig. 3). When naïve CD8+ T cells are primed by antigens and become CD8+ 
effector T cells at the first time, most of them undergo cell death very quickly after 
antigens clearance. However, some CD8+ effector T cells enter a different 
transcriptional status and become memory CD8+ T cells, which persist in tissues for a 
long time, sometimes decades (13). When memory CD8 T cells encounter the target 
antigens, they proliferate rapidly and exhibit cytotoxicity. The long-term proliferation 
and survival of memory CD8+ T cells during the secondary exposure to antigens is 
highly dependent on IL-2 secreted by CD4+ effector T cells (14, 15).  
As CD4 T cells play pivotal roles in linking innate and adaptive immune systems, 
loss or dysfunction of CD4+ T cells can result in a fatal immunodeficiency in humans. 
For example, patients with patients with a very rare mutation in the start-codon of CD4 
gene that abrogates the expression of CD4 protein and thus CD4+ T cells exhibit 
recurrent pneumonia and cannot develop a long-lived antibody response against 
pathogens. Cytotoxicity and response of innate immune cells to bacterial components 
were also dysfunctional in these patients (16). Viral infection-induced CD4+ T cell 
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depletion can also lead to fatal immunodeficiency in humans. The most well-known 
example is human immunodeficiency viruses (HIV), which infect and kill both naïve 
CD4+ T and CD4+ effector T cells over the course of years. Without actively controlling 
HIV progression by antiviral therapy, HIV infection results in higher susceptibility to 
opportunistic infection due to defective adaptive immune responses (17).  
The importance of CD4+ T cells in regulating systematic immune response is also 
shown on the recent global pandemic of coronavirus disease 2019 (COVID-19). A 
longitudinal analysis showed that patients with severe COVID-19 symptoms exhibited 
a higher degree of reduction in both CD4+ and CD8+ T cell number – a phenomenon 
called lymphopenia, than patients with moderate COVID-19 (18). A possible 
explanation is severe acute respiratory syndrome corona virus 2 (SARS-Cov2), the 
virus causing COVID-19, could directly infect and kill CD4+ T cells. SARS-CoV-2 
mainly uses its Spike protein (S protein), which binds to Angiotensin-Converting 
Enzyme 2 (ACE2), for viral entry into cells. Before binding with ACE2, S proteins need 
to be primed by protease activity from Transmembrane Protease Serine 2 (TMPRSS2) 
(19). Given that both ACE2 and TMPRSS2 are also expressed in T cells, SARS-CoV-2 
might also infect CD4+ T cells. Indeed, recent studies showed that around 50% of 
lymphocytes in circulation are infected by SARS-CoV-2 during infection (20). A recent 
study also demonstrated that SARS-CoV-2 could infect CD4+ T cells through CD4 
molecules (21). The pathological relevance and mechanism of SARS-CoV2-mediated 
killing of CD4+ T cells remain unclear and need to be further investigated. 
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Fig. 3. CD4+ effector T cells is the pivot of immune system. 
CD4+ effector T cells secrete cytokines to help class switch of B cells (top), long-term 
survival of memory CD8+ T cells (left bottom) and modulate behaviors of innate 
immune cells (right bottom). Ig: immunoglobulin.  
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Transcriptional regulation in CD4+ T cell differentiation 
Because of the pivotal roles of CD4+ effector T cells in immunity, the differentiation of 
naïve CD4+ T cells to effector T cells in lymphatic tissues can be seen as the initiation 
of systematic immune response. The differentiation process of CD4+ T cells is regulated 
by three signals provided from APC. The primary signal is mediated by the interaction 
between antigen:MHC II complexes and TCR on APC surfaces and naïve CD4+ T cells, 
respectively. The secondary signal, also called co-stimulatory signal, is activated by the 
interaction between CD80/86 and CD28. T The tertiary signal is derived from cytokines 
released by APC and activates Signal Transducers and Activator Transcription (STAT) 
proteins. STATs in turn induce expression of distinct lineage-specific transcription 
factors and direct naïve CD4+ T cell differentiation into six functionally distinct CD4+ 
effector T cell subsets: T helper 1 (Th1), Th2, Th9, Th17, follicular T helper (Tfh) and 
regulatory T (Treg) cells (22–24). This process, also called lineage specification, drives 
the formation of different CD4+ effector T cell lineages expressing unique 
transcriptional programs and effector molecules (25). Antigen, co-stimulatory, and 
cytokine signals also regulate metabolic reprogramming and apoptosis during CD4+ T 
cell differentiation. 
CD4+ T cell differentiation is regulated by various transcription factors. In addition 
to STATs and lineage-specifying transcription factors, Interferon Regulatory Factor 4 
(IRF4) and its associated Activator Protein 1 (AP-1) proteins play a critical role. In this 
section, I will introduce the role and function of these transcription factors in CD4+ T 
cell differentiation. I will then discuss how these transcription factors regulate lineage 
specification, metabolic reprogramming, and apoptosis. 
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Transcriptional regulation in lineage specification:  
STAT proteins and lineage-specifying transcription factors 
The lineage specification is initiated by both antigen and cytokine signals. Upon 
recognition of pathogen-associated molecules, APC secrete various cytokines into 
surrounding environment and create a tissue milieu. Depending on cytokines, diverse 
STAT proteins are activated and in turn induce expression of distinct lineage specific 
transcription factors, which work together with STAT proteins in the induction of 
unique transcriptional programs in diverse T helper cell subsets (Fig.4) (25). 
Th1 and Th2 cells are the first characterized T helper subsets (26). Molecules 
derived from intracellular bacteria, virus and protozoa activate APC to secrete IL-12 
and IFN-γ, which subsequently activate STAT1 and STAT4 and thereby induce T-bet 
expression (27–29). T-bet then induces the expression of IFN-γ and TNF-α to activate 
innate immune cells and CD8+ T cells as well as causing apoptosis in pathogen-infected 
cell (30, 31). T-bet also induces expression of IL-12Rβ2 – a subunit of IL-12 receptor 
with high-affinity IL-12 binding sites – which further amplifies the IFN-γ production 
and stabilizes Th1 phenotypes (32, 33). Th2-stimulating cytokines such as IL-4 are 
induced by molecules derived from helminth, debris from house dust mite (HDM) and 
fungal proteases. IL-4 activates STAT6 and thereby induces GATA3 expression in 
antigen-primed CD4+ T cells. GATA3 then direct the expression of IL-4, IL-5, and IL-
13 in Th2 cells. Th2 cytokines are required for anti-helminth immunity, however, 
unharnessed production of Th2 cytokines also lead to allergy, airway inflammation and 
hypersensitivity (34, 35).      
Th9 cells are a specialized group of CD4+ effector T cells in expressing IL-9, 
playing important roles in enhancing both host anti-helminth immunity and airway 
hypersensitivity (36). The differentiation of Th9 cells requires IL-4 and TGF-β signals 
as well as STAT6 activation (37). Linage-specifying transcription factors required for 
Th9 is Ets family transcription factor PU.1 (Fig. 4) (38). IL-9 was first thought to be 
associated with Th2 cells because IL-9 was required for anti-helminth immunity and 
IgG and IgE production – typical Th2 characteristics (39). However, later studies 
proved that when IL-4-primed CD4+ T cells are stimulated with TGF-β, they can start 
producing IL-9 and stop expressing IL-4 and GATA3 (37). Hence, IL-9-producing cells 
are also considered as a lineage of CD4+ effector T cells. 
Th17 cells can be further divided into two subtypes, based on their cytokine 
expression profiles and association with autoimmunity diseases: homeostatic and 
pathogenic Th17 cells (40, 41). homeostatic Th17 cells are induced by IL-6 and TGF-
β stimulation and secrete IL-17 and IL-10 to regulate activities of gut-resident immune 
cells (Fig. 4) (42–44). Cytokines secreted by homeostatic Th17 cells also strengthen 
tissue barriers in small intestines and help B cells to produce IgA, which is required for 
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controlling commensal microbiota in small intestines (43). On the other hand, 
pathogenic Th17 cells respond to IL-6, IL-1β, and IL-23 and secret IL-17 as well as 
proinflammatory cytokines, including IL-22, IFN-γ, and Granulocyte-Macrophage 
Colony-Stimulating Factor (GM-CSF) (45, 46). Pathogenic Th17 cells contribute to 
tissue-specific autoimmunity such as inflammation in small intestines and skin as well 
as systematic autoimmunity (45, 47, 48). In both types of Th17 cells, expression of 
STAT3 and RORγt are induced to maintain Th17 differentiation and Th17-specific 
cytokines production (49, 50).  
Tfh cells are a T helper subset specializing to help B cell development, class switch, 
and antibody affinity maturation in a transiently formed structure in lymphatic organs 
–germinal centers (51). Responding to IL-6 and IL-21, STAT3 is activated and induces 
expression of Bcl6 in antigen-primed naïve CD4+ T cells staying in germinal centers. 
Bcl6 subsequently induces expression of Tfh signature molecules, including IL-21, IL-
21 receptor (IL-21R), C-X-C chemokine Receptor type 5 (CXCR5) and Programmed 
cell Death protein 1 (PD-1) (Fig. 4). IL-21 promotes Tfh lineage stability and B cell 
development in germinal centers in autocrine and paracrine manners, respectively (52–
54). Tfh cells utilize CXCR5 to sense the chemokine CXCL13 and stay in T-B cell 
interface of germinal centers, where they continuously interact with and help B cell 
development (55). The interaction between PD-1 of Tfh cells and PD-L1/2 of B cells 
prevents the expression of CXCR3 in Tfh cells, limiting the response of Tfh cells to 
CXCL9/10 – chemokines bringing Tfh cells to leave germinal centers. Thus, CXCR5 
and PD-1 cooperatively provides signals confining the localization of Tfh cells in 
germinal centers (56).   
Unlike other T helper cell subsets, Treg cells inhibit immune responses (57). The 
differentiation of Treg cells is dependent on IL-2 and TGF-β, which activate STAT5 
and induce Foxp3 expression (58). Treg expresses anti-inflammatory cytokines such as 
IL-10 and TGF-β to inhibit activities of innate immune cells and CD4+ effector T cells. 
Treg cells also utilize their surface effector molecules CTLA-4 to interact with CD80/86, 
which interrupts the interaction of CD28 and CD80/86 and blocks the costimulatory 
signal required for activation of naïve CD4+ T cells (Fig. 4) (57, 59). In thymus, CD4+ 
T cells recognizing self-antigen with low to medium avidity can differentiate into 
thymus Treg (tTreg) cells. After maturation, tTreg cells enter circulatory system and 
peripheral lymphoid tissues as central Treg (cTreg) cells. cTreg cells exhibit a naïve-
like phenotypes, such as expressing low and high levels of CD44 and CD62L 
(CD44loCD62Lhi), respectively. Once encountering their target self-antigens in 
peripheral tissues, cTreg become activated and differentiate into effector Treg (eTreg) 
with an effector phenotype: CD44hiCD62Llo. eTreg expresses higher level of anti-
inflammatory cytokines and effector molecules such as IL-10 and CTLA-4 than cTreg. 
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eTreg are the main cell types of harnessing excessive immune activity in peripheral 
tissues (57). In addition, with the presence of TGF-β, naïve CD4+ T cells can 
differentiate into peripheral Treg (pTreg) and provide immunosuppressive functions in 
peripheral tissues (60). 
Recent evidence has suggested that effector CD4+ T cells exhibit a high plasticity. 
As we have discussed in the conversion from Th2 to Th9 cells (37), similar fate 
conversion can occur in Th17 cells (transdifferentiate into Th1 and Treg cells) (61, 62) 
and Treg (transdifferentiate into Th1) (63, 64). Multiple lineage specific transcription 
factors can also be expressed simultaneously. For example, when Tfh cells are 
stimulated in the presence of not only IL-21 but also other cytokines such as IL-12, IL-
4, IL-6 or TGF-β, in addition to Bcl6, transcription of Tbx21 (encoding T-bet), Gata3, 
Rorc (encoding RORγt), and Foxp3 can also be induced. As a result, these “Tfh-like 
cells” not only express IL-21, but also effector cytokines of other T helper lineages such 
as IFN-γ, IL-4, IL-17A and IL-10. The reciprocal plasticity also exists – when Th1, Th2, 
Th17 and Treg cells are cultured under IL-21, all T helper cell subsets express Bcl6 and 
Tfh effector molecules such as IL-21, PD-1 and CXCR5 (65). The flexibility allows 
CD4+ effector T cells to adjust its transcriptional program in response to rapid changes 
of extrinsic environment.  
 
Transcriptional regulation in lineage specification:  
IRF4, BATF and JunB 
In addition to the lineage-specifying transcription factors and STAT proteins, the 
heterodimer formed by BATF and JunB and their associate proteins IRF4 also play 
important roles in regulating CD4+ T cell differentiation. These transcription factors are 
induced by TCR and co-stimulatory signals in all the T helper subsets and act as critical 
regulators in directing lineage specification. Mice deficient with IRF4, BATF or JunB 
exhibit various impaired adaptive immunity under in vivo immunization conditions 
(Table 1).  
IRF4 was firstly cloned from B cells and later found to be also induced in both 
CD4+ and CD8+ T cells (54, 66–75). IRF4 regulates transcription of target genes 
through directly binding to Interferon-Stimulated Response Element (ISRE) of the 
proximal DNA regions. Without interacting with other proteins, however, IRF4 binds 
to ISRE only with low affinity (76, 77). This is because the DNA binding activities of 
N-terminal DNA binding domain (DBD) in IRF4 is repressed by C-terminal repression 
domain. Binding with other proteins through C-terminal repression domain could 
“release” the DNA binding ability of DBD (76, 77). Previous studies have demonstrated 
that in B cells, an ETS family protein PU.1 interacts with IRF4 to release the DBD 
domain (77). The binding sites for PU.1 and IRF4 is called as ETS-IRF4 composite 
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element (EICE) (78). In T cells, AP-1 family proteins such as BATF and Jun family 
proteins play this releasing role to help IRF4 binding to its target sites, called AP-1-
IRF4 composite element (AICE) (78, 79). 
IRF4 regulates the formation and functions of Th1, Th2, Th9, Th17, Tfh and 
effector Treg (eTreg) (Fig. 4) (54, 67, 69, 71–75, 80, 81). IRF4-deficient CD4+ T cells 
showed decreased capacity to differentiate into Th1, Th2, Th9, Th17, Tfh under in vitro 
polarizing conditions (69, 71, 73–75, 80). Accordingly, Irf4-/- mice showed impaired 
adaptive immune response mediated by Th1, Th2, Th9, Th17, and Tfh cells (Table 1). 
CD4+ T cells expressing IFN-γ and IL-4 were decreased in Irf4-/- mice infected with L. 
monocytogenes and L. major, respectively (54, 74). Irf4-/- mice also exhibited ablated 
Tfh formation in lymph nodes during L. major infection and developed resistance to 
Th17-mediated pathogenicity during EAE induction (54, 69, 70). Although Foxp3 can 
be normally induced in IRF4-deficient CD4+ T cells (69), these cells cannot express 
effector molecules such as CTLA-4 to suppress excessive immune activation in 
peripheral tissues. Severe autoimmune syndrome and high levels of serum IgG, and IgE 
were observed in mice with Irf4 deletion in Treg cells (72, 73, 82).  
AP-1 proteins were first identified as a heterodimer formed by Jun and Fos 
proteins, which promotes growth and oncogenic transformation of mammalian cells 
(83). Since then, many AP-1 proteins belonging to different subfamilies have been 
identified: Jun (Jun, JunB, and JunD), BATF (BATF, BATF-2, BATF-3), Fos (Fos, Fos-
B, Fra1, and Fra2), Maf (c-Maf, Maf-B/G/A/F/K, and Nrl), ATF and JDP subfamilies. 
All AP-1 proteins contain a basic leucine zipper (bZIP) domain, and interaction 
between bZIP domains allows two AP-1 proteins to form homodimers or heterodimers 
(84). DNA elements bound by AP-1 proteins include 12-O-tetradecanoylphorbol-12-
acetate (TPA) response elements (TRE: TGA(C/G)TCA) and cAMP response elements 
(CRE: TGACGTCA). In addition to forming heterodimers with other AP-1 proteins, 
many AP-1 proteins have a C-terminal transactivation domain that enables them to 
interact with non-AP-1 family proteins (85). 
So far, the most well documented AP-1 protein in regulating differentiation of 
CD4+ T cells is BATF (76, 86). Structural analysis of BATF proteins reveals the lack of 
a transactivation domain (TAD) (84). Without TAD, BATF cannot activate transcription 
through recruiting RNA polymerase like many other AP-1 family transcription factors. 
Studies suggest that specific BATF transcriptional activity comes from its interaction 
with other transcription factors. For example, mutations in the BATF leucine zipper 
domain, which is required for interacting with other proteins such as IRF4, impaired 
Th17 differentiation (87). BATF also interacts with chromatin remodeling proteins such 
as Ets, and CTCF (87, 88). In Th17 cell, BATF works together with chromosome-
restructuring proteins such as Ets1 and CTCF to promote chromatin accessibilities and 
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the formation of three-dimensional chromatin loops in a genome-wide scale including 
gene loci for Il17a, Il17f and Il21. The BATF-dependent chromatin opening exposes 
the promoter regions of genes for CD4+ T cells differentiation to STAT3. (88). 
Another feature of the BATF is the strong tendency of forming heterodimer with 
other AP-1 family proteins such as Jun family proteins (84). Although all Jun family 
proteins are able to form heterodimer with BATF, experimental evidence from 
electrophoretic mobility shifting assay (EMSA) and chromatin immunoprecipitation 
with PCR (ChIP-PCR) have demonstrated that BATF-JunB complex is the dominant 
heterodimer in Th2 and Th17 cells, suggesting that JunB is the major partner of BATF 
during CD4 T cell differentiation (89, 90).  
BATF regulates Th2, Th9, Th17, Tfh and eTreg differentiation (Fig. 4) (72, 89–
92). CD4+ T cells isolated from Batf-/- mice can develop into Th1, but not Th2, Th17 
and Tfh cells under in vitro polarizing conditions (89–91, 93). Consistent with those 
findings, CD4+ T cells expressing IFN-γ are not altered but IL-4-expressing CD4+ T 
cells largely decrease in Batf-/- mice infected with N. brasiliensis (90). Batf-/- mice are 
also resistant to asthma induction and have impaired generation of IL-9 production in 
vivo (94). EAE induction and the generation of IL-17-producing CD4+ T cells are 
severely inhibited in Batf-/- mice (89). Tfh-mediated immune response, such as germinal 
center formation in draining lymph nodes and class switch of B cells, are completely 
diminished in Batf-/- mice during in vivo immunization (91, 95). Foxp3 can be induced 
in BATF-deficient CD4+ T cells, but the proportion of total Treg cells in spleen are 
mildly reduced in Batf-/- mice (72, 89). However, in Batf-/- mice, the formation and 
development of eTreg are totally impaired in peripheral tissues such as visceral adipose 
(Table 1) (72). In mechanism, BATF promotes glyceride metabolism and increases the 
fitness of eTreg cells, which enables eTreg cells inhibits the production of IgE during 
allergic inflammation (96). Moreover, a mutation in Foxp3, which decreases expression 
of BATF in Treg cells, diminishes the generation of eTreg in peripheral tissues and 
causes unharnessed activation of Th1, Th2 and Th17 cells (97).  
JunB is a major heterodimeric partner for BATF in antigen-primed naïve CD4+ T 
cells (78, 79, 98). We and others have reported that JunB is required for generation of 
pathogenic Th17 cells that cause autoimmunity, but not for gut-resident homeostatic 
Th17 cells (99–101). JunB also controls effector Treg homeostasis and immune 
suppressive functions (102–104). Furthermore, JunB reportedly promotes expression 
of cytokines specific to Th2 and Th9 cells (98, 105). Thus, JunB likely contributes to 
differentiation and function of various CD4+ effector T subsets. However, in vivo roles 
and transcriptional targets for JunB in diverse T helper subsets are not fully understood.  
Our previous experiments have demonstrated that under pathogenic Th17 
culturing conditions in the presence of IL-6, IL-23, and IL-1β, the generation of Th-17 
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cells is impaired in JunB-deficient CD4+ T cells. On the other hand, under non-
pathogenic Th17 culturing conditions in the presence of TGF-β and IL-6, the 
differentiation of Th17 cells is moderately affected. Accordingly, mice with Junb 
deletion in CD4+ T cells are resistant to EAE and colitis induction, both of which are 
mediated by pathogenic Th17 cells. However, the generation of gut-resident 
homeostatic Th17 cells are not affected in Junb-deficient mice (Table 1) (100)(101). As 
with BATF and IRF4, JunB is required for eTreg but not for total Treg. Foxp3 can be 
induced in JunB-deficient CD4+ T cells, but the frequency of total Treg cells is not 
affected in T cell-specific Junb-deficient mice (Table1) (104). However, JunB-deficient 
Treg cells lose its ability to inhibit cytokine production from Th1, Th2 and Th17 in vitro 
(102).  
The role of JunB in Th1 differentiation remains unclear and even controversial. 
Two independent studies have demonstrated inconsistent results that expression of IFN-
γ was either not altered or upregulated in JunB-deficient Th1 cells. Mice with different 
genetic backgrounds in these studies may account for this inconsistency. Whether JunB 
deletion affects in vivo Th1-mediated response has not been studied (99, 101).  
A previous study has demonstrated the requirement of JunB in production of Th2 
effector cytokine such as IL-4 and promoting airway inflammation (105). However, 
mice used in this study are a systematic knockdown strain, not the commonly-used 
conditional knockout mice strains (Table1) (105). Thus, the artificial effects of this 
systematic knockdown technique on Th2 effector cytokines production could not be 
verified. Moreover, this study could not exclude the possibility that the attenuated 
airway inflammation could be due to reduced JunB expressions in innate immune cells 
but not in CD4+ T cells. 
In summary, compared to the well documented roles of BATF and IRF4 in lineage 
specification, the functions of JunB in Th1 and Th2 differentiation and corresponding 
in vivo immune responses are less understood.   
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Fig. 4. Transcriptional regulation in lineage specification 
Antigens derived from different sources activate antigen presenting cells (APC) to 
secrete various cytokines, creating specific cytokine milieu and direct the lineage 
specification of CD4+ effector T cells. Depending on cytokines, distinct signaling 
transducer and activator of transcription (STAT) family proteins are activated, which 
subsequently induce the expression of lineage specifying transcription factors. In 
addition, IRF4, BATF and JunB, which are induced by TCR and costimulatory signals, 
work together with STAT proteins and lineage specifying transcription factors to 
induce expression of lineage-specific effector molecules in each T helper cell subset.  
Compared to IRF4 and BATF, the roles of JunB in lineage specification of Th1, Th2 
and Tfh cells remain unclear or controversial. TGF-β: transforming growth factor β; 
IFN-γ: interferon gamma; CTLA-4: cytotoxic T lymphocyte-associated protein 4; 
CXCR5: C-X-C motif chemokine receptor 5; T-bet: T-box expressed in T cells; 
GATA3: GATA-binding protein 3; RORγt: RAR-related orphan receptor gamma.   
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Table 1. A summary of impaired adaptive immunity in mice deficient with IRF4, 
BATF and JunB  
Protein Phenotypes related to each T helper cell subset References 
IRF4 Th1: Impaired expression of IFN-γ and TNF-α in CD4+ T cells during 
bacterial infection (L. monocytogenes) a. 
Th2: Impaired expression of IL-4 in CD4+ T cells and susceptible to 
helminth infection (L. major) a.  
Th9: Impaired expression of IL-9 in CD4+ T cells and increased 
resistance to asthma induction a. 
Th17: Impaired expression of IL-17 in CD4+ T cells and increased 
resistance to EAE induction a.  
Tfh: Deficiency in generating germinal center in draining lymph nodes 
during helminth infection (L. major) a. 
eTreg: Impaired generation of eTreg, abnormally increased serum 
antibodies, and developed in autoimmune disease d. 
(54, 69–72, 
74, 75, 80, 
81) 
BATF Th1: Unaltered expression of IFN-γ in CD4+ T cells during bacterial 
helminth infection (L. major) a. 
Th2: Impaired expression of IL-4 in CD4+ T cells and higher 
susceptibility to helminth infection (N. brasiliensis) b. 
Th9: Impaired expression of IL-9 in CD4+ T cells and increased 
resistance to airway inflammation b. 
Th17: Impaired expression of IL-17 in CD4+ T cells and increased 
resistance to EAE induction b. 
Tfh: Deficiency in CD4+ T cell-dependent class switch and deficiency 
in generating germinal center in draining lymph nodes during in vivo 
immunization b. 
eTreg: Impaired generation of eTreg, abnormally increased serum 
antibodies, and developed in autoimmune disease b. 
(72, 90, 91, 
94, 96, 106, 
107) 
JunB Th1: No report. 
Th2: Impaired expression of IL-4 in CD4+ T cells and increased 
resistance to airway allergy induction f. 
Th9: Decreased expression of IL-9 in CD4+ T cells g.  
Th17: Impaired expression of IL-4 in CD4+ T cells and increased 
resistance to EAE induction. No influence of gut-resident CD4+ T cells 
expressing IL-17 h, i. 
Tfh: No report.  
eTreg: Impaired generation of eTreg, abnormally increased serum 
antibodies, and developed in autoimmune disease h. 
(98–103, 
105) 
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a. Irf4-/- mice (54, 69–71, 74). 
b. Batf-/- mice (89–91). 
c. BatfΔZ/ΔZ mice (94). 
d. Foxp3creIrf4fl/fl mice (72).  
e. Foxp3creBatfffl/fl mice (72). 
f. Ubi-JunB / Junb-/- mice, a transgenic Junb-/- mice strain expressing JunB under the 
control of human ubiquitin C promoter, which causes a systematic JunB 
knockdown in mice (105).   
g. siRNA targeting Junb in mouse CD4+ T cells (98). 
h. Cd4creJunbfl/fl mice (100, 101).  
i. Meox2creJunbfl/fl mice (99). 
j. Foxp3creJunbfl/fl mice (102).  
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Transcriptional regulation in metabolic reprogramming  
Cells utilize several metabolic pathways to obtain bioenergy and metabolites for 
building blocks. When cells are in the resting state, glycolysis, β-oxidation, and 
glutaminolysis pathways converge to Tricarboxylic Acid (TCA) cycles, in which a 
series of redox reactions occur to transfer electrons from metabolites to electron 
acceptors such as Nicotinamide Adenine Dinucleotide (NAD+). The electron transfer 
process couples with the transfer of protons in the inner membrane space of 
mitochondria, generating the gradient of protons across mitochondrial membranes and 
driving the synthesis of Adenosine Triphosphate (ATP) – the major source of bioenergy 
(Fig. 5). Because the terminal acceptor of this electron transfer process is oxygen, the 
process of obtaining energy in mitochondria is also called oxidative phosphorylation 
(OXPHOS). In contrast, the energy generation from glycolysis in cytoplasm does not 
require oxygen and is sometimes called anaerobic respiration (108).       
Although OXPHOS is an efficient pathway for cells to obtain energy, it requires a 
longer time than glycolysis. Hence, to meet the high demands for bioenergy in activated 
T cells, cellular metabolism is usually shifted from OXPHOS to glycolysis (Fig. 4) (109, 
110). In fact, recent studies also suggested that this metabolic reprogramming to 
glycolysis is used for immediate supply of energy and building materials. For examples, 
Th17 cells obtain acetyl-CoA as precursors for fatty acid synthesis through glycolysis 
during its rapid differentiation and proliferation (Fig. 5) (111).  
Transcriptional regulation underlying the metabolic reprogramming in activated T 
cells is controlled by Hypoxia-Inducible Factor 1 (HIF1) (Fig. 5). In the resting state, 
oxygen molecules are sufficient and easily diffuse across cell membrane. Inside the cell, 
oxygen molecules bind to prolyl-4-hydroxylase (PHD) protein, which further 
hydroxylate HIF1α and results in its degradation. During infection, however, tissues 
are under hypoxia conditions, allowing HIF1α becomes stabilized and dimerizes with 
HIF1β to form HIF-1. HIF-1 can translocate into nucleus and act as a transcription 
factor that upregulates many genes required for glycolysis (112).  
The expression of HIF1α and metabolic reprogramming in CD8+ T cells is 
controlled by IRF4 (Fig. 4B). Deletion of IRF4 in CD8+ effector T cells decreased 
expression of HIF1α and glycolysis activities but increased OXPHOS activities, 
suggesting that IRF4 is essential for metabolic reprogramming toward glycolysis. IRF4 
upregulates expression of genes for glycolysis such as glucose transporter GLUT4 and 
glycolytic enzymes Hexokinase 2 (HK2) in CD8 effector T cells (68). Similarly, IRF4 
plays essential roles in maintaining Th1 effector function through upregulating 
expression of Hk2 and Glucose Transporter 3 (GLUT3) but not HIF1α. Accordingly, 
glycolysis is completely diminished in IRF4-deficient Th1 cells, and IRF4-deficient 
mice exhibit impaired expression of Th1 signature cytokines such as IFN-γ and TNF-α 
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in CD4 T cells during L. monocytogenes infection.  Although IRF4-deficient Th1 cells 
also showed impaired OXPHOS activities, the mechanism of IRF4 -dependent 
regulation of OXPHOS is still unclear (74). 
Similar to IRF4, BATF promotes both glycolysis and OXPHOS activities in CD8+ 
effector T cells through directly upregulating the expression of HK2 and HIF1α (Fig. 
5B) (106, 113). Moreover, BATF also increases cellular NAD+ through inhibiting 
expression of NAD+-dependent deacetylase Sirt1 (106). The increased NAD+ could 
serve as electron acceptors and boost both glycolysis and OXPHOS activities during T 
cell activation (106). 
Critical roles of IRF4 and BATF in regulation of metabolic activities during T cell 
activation suggest the involvement of JunB in this regulation; however, whether JunB 
deletion affects glycolysis and OXPHOS activities in diverse T helper cell subsets 
remain to be determined 
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Fig. 5. The transcriptional regulation in metabolic reprogramming during CD4+ 
T cell differentiation. 
During differentiation, CD4+ T cells need to proliferate and produce effector molecules 
within a short time window. To meet the high demands of bioenergy and building 
molecules, the metabolic activities in activated CD4+ T cells shift from oxidative 
phosphorylation to glycolysis. This metabolic reprogramming process is 
transcriptionally regulated by Hypoxia Inducible Factor 1 (HIF1) as well as by IRF4 
and BATF. Compared to IRF4 and BATF, whether JunB regulates metabolic activities 
during T cell activation has not been reported yet. Pathways activated in each stage are 
highlighted as red. The gene encoding HIF1α subunit of HIF1 protein is 
transcriptionally regulated by IRF4 and BATF and is shown as red dashed lines. Genes 
involved in each pathway and transcriptionally regulated by indicated transcription 
factors are also shown as red dash lines. APC: antigen presenting cells; CD: Cluster of 
Differentiation; TCA cycle: Tricarboxylic cycle; ATP: Adenosine Triphosphate.  
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Transcription regulation in apoptosis 
In response to antigen signal a single naïve CD4+ T cell can proliferate and generate 
thousands of effector CD4 T cells to elicit immune response (114). The frequency of 
effector CD4+ T cells should be under extensive regulation during immune responses 
to minimize the damages to tissues, especially when antigens are removed. In 
vertebrates, hosts have evolved a mechanism called Activation-Induced Cell Death 
(AICD) by which most of activated T cells undergo apoptosis after antigen clearance 
(115).  
Two apoptosis pathways are activated in AICD – extrinsic and intrinsic pathways, 
which are mediated by FS-7-Associated Surface antigens (Fas) and proapoptotic 
molecules Bcl-2-interacting mediator of cell death (Bim), respectively (Fig. 6). The 
extrinsic pathway is initiated by the interaction between Fas and its ligand FasL on 
surface of activated T cells, which recruits the adaptor FAS-associated death domain 
protein (FADD) and procaspase 8. Cleavage of procaspase 8 generates active caspase 
8 which triggers a downstream caspase cascade that involves caspase 3 (Fig.6) (116). 
On the other hand, intrinsic signals activated by various stimuli such as oxidative stress, 
calcium flux, and IL-2 deprivation stabilize Bim proteins or trigger the degradation of 
B Cell Lymphoma 2 (Bcl2) – a protein that can bind with Bim and neutralize its 
proapoptotic activities (117). Bim then induces oligomerization of Bak/Bax proteins 
and pore formation on the outer membrane of mitochondria, causing release of 
cytochrome c into cytoplasm. Cytochrome c subsequently activates the cleavage of 
procaspase 9 which converge into a downstream caspase 3 cascade (118).  
Apoptosis pathways are transcriptionally regulated by IRF4 and BATF. Both IRF4 
and BATF inhibit transcription of Fasl, Bcl2l11 (encoding Bim) and Casp3 (encoding 
Caspase 3) (68, 79, 113, 119). Deletion of either IRF4 or BATF increase apoptotic cell 
population in CD8 effector T cells (68, 113). Moreover, overexpression of BATF in 
both CD4+ and CD8+ T cells inhibit apoptosis and induce lymphoproliferative disorders 
in mice (120). Taking these together, expression of IRF4 and BATF in activated T cells 
is required for repressing expression of apoptosis initiators to control apoptosis before 
antigen clearance. 
The cytoplasmic abundance of Bim is not only regulated by IRF4 and BATF, but 
also by Forkhead box O3 (Foxo3). In healthy cells, growth factors such as cytokines 
stimulate Akt to phosphorylate Foxo3 and to inhibit its activity. Once IL-2 are deprived, 
Foxo3 is activated and promotes the transcription of Bcl2l11 (121, 122). Deprivation of 
cytokines also prevents Erk1/2-mediated phosphorylation of Bim on its serine 69 
residue, which promotes ubiquitylation and degradation of Bim through proteosome 
pathway (118, 123). 
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However, little is known about whether JunB is involved in regulating apoptosis 
in activated CD4+ T cells. Our lab has demonstrated that JunB deletion in Treg cells 
increased the accumulation of apoptotic effector Treg in peripheral tissues (102). Hence, 
it is possible that JunB may promote cell survival in CD4+ T cells during TCR 
stimulation across diverse T helper cell subsets. Whether JunB, like BATF and IRF4, 
could directly bind and inhibit transcription of apoptosis initiators such as FasL and 
Bim, remains unknown. 
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Fig. 6. The transcriptional regulation of apoptosis during CD4+ T cell 
differentiation.  
Extrinsic and intrinsic apoptosis pathways are induced to ensure most of activated CD4+ 
T cells undergo cell death after antigen clearance. The extrinsic pathway is induced by 
interaction of FS-7-Associated Surface antigens (Fas) and its ligand FasL. Fas then 
recruits the adaptor FAS-associated death domain protein (FADD) and induces the 
cleavage of procaspase 8. The intrinsic pathway is triggered by intrinsic stimuli such as 
oxidative stress or IL-2 deprivation, which subsequently either facilitate the 
degradation of B Cell Lymphoma 2 (Bcl-2) or stabilize proapoptotic molecules Bcl-2-
interacting mediator of cell death (Bim). Bim then induces oligomerization of Bak/Bax 
proteins and pore formation on the outer membrane of mitochondria, causing release of 
Cytochrome c (Cyt c). Both pathways converge into activation of  caspase 3. Caspase 
3 then induces cleavages of cellular substrates and apoptosis. These two pathways are 
transcriptionally regulated by IRF4, BATF and Forkhead box O3 (Foxo3). Whether 
JunB regulates apoptosis during T cell activation has not been reported yet. Apoptotic 
molecules positively and negatively regulated by indicated transcription factors are 
highlighted as red and blue lines, respectively.  




IRF4 and BATF play critical roles in regulating a broad spectrum of biological functions 
together with STAT proteins and lineage specifying transcription factors. The major 
BATF partner, JunB, is critical for Th17 and eTreg differentiation and functions, but its 
role in other effector CD4 T subsets is not fully understood. The aim of this thesis is to 
reveal roles and function of JunB in Th1 andTh2 cells and to understand common and 
cell-type-specific JunB-dependent transcriptional program in effector CD4 T subsets.   
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Chapter 2: Method and materials 
 
Mice. 
Floxed Junb (Junbfl/fl) mice have been described previously (100). Cd4cre (stock# 
017336), OT-II (stock# 004194), Rag1-/- (stock# 002216), and B6SJL (stock# 002014) 
mice were obtained from the Jackson Laboratory. All mice were maintained on a 
C57BL/6 background under specific pathogen-free conditions. Sex-matched, 6–12-
week-old mice were used for experiments. All animal experimental protocols were 
approved by the Animal Care and Use Committee at Okinawa Institute of Science and 
Technology Graduate University.  
 
Isolation of naïve CD4+ T cells. 
Murine naïve CD4+ T cells were purified from pooled spleens by negative selection 
using MojoSort mouse naïve CD4+ T cell selection kit (480039; Biolegend), in 
accordance with manufacturer’s instructions. Flow cytometry analysis confirmed that 
the purity of CD4+CD25-CD62LhiCD44lo cells ranged from 90% to 95% (Fig. 7A). 
 
Cell culture. 
Murine naïve CD4+ T cells were purified with MojoSort mouse naïve CD4+ T cell 
selection kit as described in previous section. Purified naïve CD4+ T cells were cultured 
in 24-well (4 x 105 cells per well), 48-well (2 x 105 cells per well) or 96-well (1 x 105 
cells per well) plates coated with 5 µg/mL anti-CD3ε antibody (145-2C11; Biolegend) 
in IMDM medium (12440-061; Invitrogen) containing 1 µg/mL anti-CD28 antibody 
(37.51; Biolegend), 10% FBS, 1x streptomycin-penicillin (containing 100 U/ml 
penicillin and 100 mg/mL streptomycin, P4333; Sigma), and 55 mM β-mercaptoethanol 
(20985-023; Invitrogen). In addition, the following cytokines were added in each 
polarizing condition: 20 ng/mL IL-2 (570402; Biolegend), 1 µg/mL anti-IFN-γ 
(XMG1.2; Biolegend), and 1 µg/mL anti-IL-4 (11B11; Biolegend) for Th0; 20 ng/mL 
IL-2, 20 ng/mL IL-12 (577002; Biolegend), and 1 mg/mL anti-IL-4 for Th1; 20 ng/mL 
IL-2, 100 ng/mL IL-4 (574306; Biolegend), and 1 mg/mL anti-IFN-g for Th2; 20 ng/mL 
IL-6 (575706; Biolegend), and 3 ng/mL TGF-β1 (100-21C; PeproTech) for Th17. 
Polarized cells were harvested for further analysis at the indicated time points.  
 
Adoptive transfer. 
Naïve CD4+ T cells isolated from Junbfl/fl OT-II or Junb fl/flCd4cre OT-II mice (CD45.2+) 
were mixed with naïve CD4+ T cells isolated from congenic OT-II mice 
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(CD45.1+CD45.2+) at a ratio of 2:1. Cells (3 x 106 cells per mouse) were intravenously 
injected into congenic recipient B6SJL mice (CD45.1+). 
 
Immunization. 
One day after adoptive transfer, mice were anesthetized with isoflurane and immunized 
with 20 mg of OVA peptide 323-339 (ISQAVHAAHAEINEAGR, GL Biochem) 
emulsified in 100 mL complete Freund’s adjuvant (CFA) or mixed with 10 mg of 
lipopolysaccharides (LPS) from Escherichia coli O111 (L4391; Sigma;) or 40 mg 
papain (P5306; Sigma). CFA was prepared from 100 mL incomplete Freund’s adjuvant 
(263910; BD) and 1 mg desiccated Mycobacterium tuberculosis H37 Ra (231141; BD) 
according to the manufacturer’s instructions and emulsified with OVA peptide using an 
ultrasonic homogenizer (VP-050; TAITEC) on ice for 30-45 min. LPS and papain were 
dissolved in PBS and mixed with OVA peptide at room temperature before 
immunization. For immunization with CFA or LPS, mice were injected subcutaneously 
on each side close to the base of tail. For immunization with papain, mice were injected 
intranasally with 40 ug papain each time for two consecutive days. Analysis was 
conducted at indicated number of days post immunization (dpi). 
 
Lymphopenia induced cell proliferation assay.  
Naïve CD4+ T cells isolated from Junbfl/fl or Junb fl/flCd4cre mice (CD45.2+) were mixed 
with naïve CD4 T cells isolated from congenic mice (CD45.1+CD45.2+) at a ratio of 
1:1. Cells (1 x 106 cells per mouse) were intraperitoneally injected into congenic 
recipient B6SJL mice (CD45.1+). 14 days post transfer, single cell suspension from 
spleens and inguinal lymph nodes of Rag1-/- mice were made by mildly pushing spleens 




For flow cytometry analysis, the following antibodies were used with a 1:100 dilution: 
anti-CD3 (17A2; Biolegend), anti-CD4 (GK1.5; Biolegend), anti-CD25 (PC61; 
Biolegend), anti-CD44 (IM7; Biolegend), anti-CD62L (MEL-14; Biolegend), anti-
CD45.1 (A20; Biolegend), anti-CD45.2 (104; Biolegend), anti-FasL (MFL3; 
Biolegend), anti-IL-17A (TC11-18H10.1; Biolegend), anti-IFN-γ (XMG1.2; 
Biolegend), anti-JunB (C-11; Santa Cruz Biotechnology), anti-GATA3 (16E10A23; 
Biolegend), anti-ROR-γt (Q31-378; BD), anti-T-bet (4B10; Biolegend), and anti-rabbit 
IgG (Poly4064; Biolegend). For ChIP analyses, anti-JunB (2 μg per ChIP, 210; Santa 
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Cruz), anti-BATF (2 μg per ChIP, WW8; Santa Cruz), and anti-IRF4 (2 μg per ChIP, 
M-17; Santa Cruz) were used.  
 
Flow cytometry.  
For analysis of cell surface molecules, cells were stained with their antibodies and 
Zomibe-NIR (1:400, 423106; Biolegend) in PBS containing 2% FBS for 30 min on ice. 
For analysis of intracellular molecules, cells were stained with a Foxp3 Staining Buffer 
Set (00-5253-00; eBioscience) according to the manufacturer’s protocol. For analysis 
of intracellular cytokines, cells were re-stimulated with 100 ng/mL phorbol 12-
myristate 13-acetate (P8139; Sigma) and 1 mg/mL ionomycin (I0634; Sigma) in the 
presence of 10 μg/mL brefeldin A (420601; Biolegend) for 4 h, and then stained with a 
Foxp3 Staining Buffer Set. For analysis of cells isolated from spleens and lymph nodes 
(Fig. 16-19), cells were incubated with anti-CD16/CD32 (1:100, 93; Biolegend) before 
antibody staining. The gating strategy for flow cytometry analysis and fluorescence 
minus one (FMO) control data are described in Fig. 7 and Fig. 8. 
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Fig. 7. Purity of naïve CD4+ T cells and gating strategies for flow cytometry 
analysis of CD4+ T cells cultured under in vitro polarizing conditions. 
(A) Flow cytometry purity analysis of murine naïve CD4+ T (CD4+CD25-
CD62LhiCD44lo) cells. (B) Gating strategies for all in vitro polarizing cultures (related 
to Fig. 12 -14). (C) Gating strategies for flow cytometry analysis of transferred OT-II 
cells (CD45.1+45.2+) and recipient CD4+ T cells (CD45.1+). Flow cytometry analysis 
of the fluorescence minus one (FMO) control group for JunB in transferred OT-II cell 
is shown (related to Fig. 15, 17).  
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Fig. 8. Gating strategies for flow cytometry analysis 
(A) Gating strategies for flow cytometry analysis of transferred control OT-II (Junbfl/fl) 
or JunB-deficient OT-II (Junbfl/flCd4cre) (45.2+) and co-transferred congenic OT-II 
CD4+ T cells (CD45.1+45.2+) (related to Fig. 16). (B) Gating strategies for flow 
cytometry analysis of CD4+ T cells of transferred control CD4+ T cells (Junbfl/fl) or 
Junb-deficient CD4+ T cells (Junbfl/flCd4cre) (CD45.2+) and co-transferred congenic 
CD4+ T cells (CD45.1+) from Rag1-/- mice (related to Fig. 18). 
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Preparation of ribonucleoprotein (RNP) complex. 
The ribonucleoprotein (RNP) complex was prepared as described in detail previously 
(124). Guide RNA targeting Junb (gJunB) or negative control guide RNA (gNTC, 
1072544) were purchased from Integrated DNA Technology. In short, guide RNA was 
first mixed with tracrRNA (1072535; Integrated DNA Technology) in equal molar 
concertation at room temperature for 10 min. RNA mix was then annealed by heating 
at 95°C for 5 min in a thermocycler (TP600; Takara) and slowly cooled to 25°C. For 
one nucleofection reaction, the RNP complex was prepared by mixing 150 nmol 
gRNA:tracRNA duplex with 60 nmol Cas9 protein (A36498; Invitrogen) at room 
temperature for 10 min right before nucleofection.    
 
Table 2. List of guide RNA 







Nucleofection of naïve CD4+ T cells. 
Nucleofection of naïve CD4+ T cells was performed with P4 primary cell nucleofector 
kit (V4XP-4024; Lonza) following the manufacturer’s protocol (124). Up to 1 x 107 
purified naïve CD4+ T cells from C57BL/6 mice were washed with PBS, suspended 
with 20 mL P4 primary cell nucleofector solution and mixed with 5 mL of RNP complex 
at room temperature for 2 min in a round-bottom 96-well plate. The cell/RNP mix was 
transferred to nucleofection cuvette strips, and CD4+ T cells were electroporated using 
Lonza 4D Nucleofector X unit (program code: DS137). After nucleofection, 200 mL 
prewarmed RPMI was added to a cuvette to transfer cells into flat-bottom 96-well plates. 
1 x 106 cells were then rested in RPMI containing 5 ng/mL IL-7 (577802; Biolegend), 




To determine the metabolic activities, Oxygen consumption rate (OCR) and 
extracellular acidification rate (ECAR) were measured by using mito stress (103015-
100; Agilent Technologies) and glycolysis stress kits (103020-100; Agilent 
Technologies), respectively. These two assays first measured the basal level of 
metabolic activities and then measured the altered metabolic rates when cells were 
sequentially treated with various reagents (Fig. 10). Naïve CD4+ T cells were cultured 
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under Th1-, Th2- and Th17-polarizing conditions for 48 h and transferred to the analysis 
plate (2 x 105 cells per well). The analysis plate was first coated with 50 mL of 2% 
gelatin (G1890; Sigma) and pre-incubated at 37 oC for 1 h. To measure basal OCR, cells 
were incubated with XF base medium supplemented with 1 mM pyruvate (11360070; 
Gibco), 2 mM glutamine (A2916801; Gibco) and 10 mM glucose (A2494001; Gibco) 
for the first 20 minutes. Cells were then subsequently treated with 1.5 μM oligomycin, 
1 μM fluorocarbonyl cyanide phenylhydrazone (FCCP) and 0.5 μM rotenone/antimycin 
A mix (103015-100; Agilent Technologies). To measure basal ECAR, cells were 
incubated with XF base medium supplemented with 2 mM glutamine for the first 
20minutes. Cells were then treated with 10 mM glucose, 1 μM oligomycin, and 50 mM 
2-deoxyglucose (2-DG) (103020-100; Agilent Technologies). The OCR and ECAR 
were analyzed using a Seahorse XFe96 analyzer (Seahorse Bioscience), according to 
the manufacturer’s instructions. 
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Fig. 9. Metabolic rates measured by seahorse assay.  
Oxygen consumption rate (OCR) and Extracellular acidification rate (ECAR) were 
measured by seahorse in in-vitro differentiated T helper cells. (A) In OCR analysis, 
basal respiration is measured first, and respiration activities in each phase are measured 
from cells sequentially treated with oligomycin, fluorocarbonyl cyanide 
phenylhydrazone (FCCP), rotenone and antimycin A. (B) In ECAR analysis, basal 
glycolysis activity is fist measured from cells treated with glucose, and then glycolytic 
activities in each phase are measured from cells sequentially treated with oligomycin 
and 2-Deoxy-D-Glucose (2-DG).  
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Enzyme-Linked Immunosorbent Assay (ELISA) 
Concentrations of IFN-γ and IL-13 in supernatant from in-vitro differentiated T helper 
cell culture were determined by ELISA using Mouse IFN-γ  (430801; Biolegend) 
ELISA MAX Standard kit and Mouse IL-13 Uncoated ELISA kit (88-7137; Invitrogen), 
respectively, following manufacturers’ instructions. Flat-bottom, 96-well plates 
(Greiner, 655061) were coated with anti-mouse IFN-γ (1:200, Biolegend) and anti-
mouse IL-13 (1:250, Invitrogen) capture antibodies overnight at 4oC. Plates were 
washed with 0.05% Tween20 (9005-64-5; Sigma) in PBS (PBST) and blocked with 
PBS containing 1% bovine serum albumin (BSA, 018-15154; Wako) for 1 h at room 
temperature. Samples were diluted with PBS containing 1% BSA (no dilution or 1:100 
for IFN-γ and 1: 100 for IL-13) and incubated for 3 h at room temperature. Plates were 
then washed and incubated with the following biotin-conjugated antibodies for 1 h at 
room temperature: anti-mouse IFN-γ (1:200) and anti-mouse IL-13 (1:250). Plates were 
incubated with streptavidin conjugated with horse-radish peroxidase for 30 min at room 
temperature and incubated with TMB (T0440; Sigma) for another 15 min. The reaction 
was stopped by adding 50 µl of 2N sulfuric acid, and absorbance at 450 nm and 570 
nm was read using ELISA plate reader (iMark; Bio-rad). 
 
RT-qPCR. 
Total RNA were isolated from cells using RNeasy Plus Mini Kit (74136; Qiagen). The 
amounts of RNA was determined by spectrophotometer (Nanodrop 2000; Thermo) and 
200 ng of RNA were subsequently used for cDNA synthesis with Revertra Ace qPCR 
Kit (FSQ-101; Toyobo). The resulting cDNA was used as a template for qPCR 
performed with Faststart SYBR master mix (4673484; Roche) and thermal cycler 
(Thermal Cycler Dice Real Time system III; Takara). Primers used for qPCR are listed 
below. 
 
Table 3. Lists of RT-qPCR primers 
Primer ID Sequence Length of 
amplicons (bp) 
Junb_F GACCTGCACAAGATGAACCACG 129 
Junb_R ACTGCTGAGGTTGGTGTAGACG 




Naïve CD4+ T cells were cultured under Th0-, Th1- and Th2-polarizing conditions for 
48 h. Then, cells were stained with Zombie-NIR (1:400, 423105; Biolegend), and viable 
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cells were sorted with FACS. RNA samples were prepared using Trizol (Invitrogen) 
with a Qiagen RNAeasy kit (Qiagen). Before sequencing, Junb mRNA level was first 
confirmed by RT-qPCR, as described in previous section. Total RNA was provided to 
the OIST DNA sequencing section for library preparation and sequencing. cDNA 
libraries for RNA-Seq were prepared with an NEBNext Ultra II Directional RNA 
Library Prep Kit for Illumina (E7760L; New England BioLabs) and purified using 
Agencourt AMPure XP beads (A63880; Beckman Coulter) following the 
manufacturer’s instructions. Adapter dimers in cDNA libraries were removed with a 
LabChip NGS 3K reagent kit (CLS960013; PerkinElmer) and confirmed using a 
TapeStation (Agilent). Purified cDNA libraries were quantified with droplet digital 
PCR (BioRad QX-200 system). Sequencing was performed on an Illumina NovaSeq 
6000 to generate 150-nucleotide paired-end reads at a read depth of at least 20 million 
reads per sample.   
 
Differential gene expression analysis. 
Raw reads from RNA-Seq were first trimmed with Cutadapt 2.10 (125). Trimmed reads 
were then directly mapped to the UCSC mouse genome mm10, and transcripts were 
quantified with Salmon 1.3.0 using default settings. To provide gene annotation, a 
mouse genome index was used during transcript quantification with a k value of 31 
(126). After transcript quantification, raw feature counts of each transcript were first 
normalized within and between samples to obtain TPM (Transcripts Per kilobase 
Million). Differential gene expression analysis was conducted with DeSeq2 (127). 
Three or four independent biological samples were used for the analysis. Genes that 
were differentially expressed in Junb-deficient vs control cells (log2 Fold change < -
0.5 or > 0.5, p value < 0.05, base mean > 100) were selected for pathway analysis using 
Enrichr (128, 129). 
 
ChIP-Seq. 
ChIP-Seq samples were prepared using a SimpleChIP Plus Enzymatic Chromatin IP 
Kit (9005S; Cell Signaling) as previously described (100). Naïve CD4+ T cells from 
Junbfl/fl (WT) mice were cultured under Th1-polarizing conditions. After 48 h, activated 
cells (0.5-1 x 106 per ChIP-seq) were cross-linked in culture medium containing 1% 
formaldehyde at room temperature for 10 min, and glycine solution was added to stop 
the reaction. Then fixed cells were lysed and nuclei were isolated and treated with 
micrococcal nuclease (0.00313 μL/mL) for 20 min at 37°C. The nuclease reaction was 
stopped by adding 0.05 M ethylenediaminetetraacetic acid (EDTA). Samples were then 
sonicated to disrupt nuclear membranes and centrifuged to collect supernatants 
containing chromatin. Chromatin solutions were incubated with 1 μg of antibodies 
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overnight at 4°C with rotation, and complexes of antibodies and chromatin were 
collected with Dynabeads Protein G (10004D; Invitrogen). Beads were washed with 
low-salt and high-salt solutions five times and three times, respectively, and incubated 
5 min for each washing at 4°C. Chromatin was eluted, de-cross-linked following the 
manufacturer’s instructions, purified by phenol/chloroform extraction, and used for 
ChIP-sequencing. To generate DNA sequencing libraries, DNA was blunt-ended and 
ligated with adaptors using a KAPA Hyper Prep Kit (KK8500; KAPA Biosystems). 
Adaptor-ligated DNA was then cleaned up with an Agencort AMPure XP (A63880; 
Beckman Coulter) at a 1.8 x DNA ratio, amplified by PCR, and purified using the 
AMPure XP at a 1.2 x DNA ratio. Library DNA was size-selected using a 2% agarose 
gel cassette of Blue Pippin (Sage Science) for a target size range 150-300 bp and 
quantified with droplet digital PCR (BioRad QX-200). Sequencing was performed on 
an Illumina HiSeq 4000 to generate 150-nucleotide single-end reads at a read depth of 
at least 20 million reads per sample.   
 
ChIP-Seq peak calling, annotation, and visualization.  
Raw reads of ChIP-Seq were obtained as described above (for Th1) or from GSE86535 
(for Th17) and GSE121295 (for Treg) (100, 102). Raw reads from Th1, Th17 and Treg 
were trimmed using Cutadapt 2.10 (125). Trimmed reads were then mapped to mouse 
genome mm10 by calling Bowtie2 2.3.4.3 in TopHat2 2.1.1 (126, 130). Peaks were 
called for each sample replicate using Homer 4.11 with default parameters (FDR < 
0.001) and a combined peak dataset was obtained from the union of Th1, Th17, and 
Treg dataset. To annotate peaks, they were assigned to the nearest genes using the 
annotatePeaks function in Homer v4.11. To visualize peaks, in Homer v4.11, a mapped 
read tag directory was first created by calling the makeTagDirectory function and a bed 
graph file was generated based on this Tag directory (130). Overlapping ChIP-Seq 
peaks for JunB, BATF and IRF4 were identified using bedtools functions with the 
following parameters, f=0.5 and -r (131). 
 
Motif scan. 
JunB-binding motifs across the mouse genome were identified using the 
scanMotifGenomeWide.pl function in Homer v4.11 (mm10). The AP-1-binding motif, 
RATGASTCAT, was used for this motif scan. Genomic regions containing AP-1 motifs 
were assigned to their nearest genes using the annotatePeaks function in Homer v4.11 
(130). 
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Prediction of direct and indirect JunB responsive genes with BETA analysis. 
Using RNA-seq data, I first defined genes that were differentially expressed in Junb-
deficient vs control cells (log2 Fold change < -0.5 or > 0.5, p value < 0.05, base mean 
> 100) as JunB responsive genes. Next, I associated JunB responsive genes with ChIP-
seq peaks for JunB and overlapping ChIP-seq peaks for JunB, BATF, and IRF4, as well 
as AP-1 motifs. I calculated the regulatory potential (RP) of each gene with the 
following equation (132): RP score =  ∑  𝑘𝑘𝑖𝑖=1 𝑒𝑒−(0.5+4∆𝑖𝑖), where k equals the number 
of all binding peaks/motif within ± 10 kbp of the gene (132). ∆ is distance to 
transcription starting site (TSS) of the gene, normalized to 100 kb. For example, ∆ = 
0.1 means the ChIP-seq peak or AP-1 motif is within 10 kb from TSS of the gene. A 
higher RP score indicates a greater density of ChIP-Seq peaks or AP-1-binding motifs 
within 100 kb of the TSS of the nearest gene. I then calculated the BETA score with the 
following equation (133): BETA = (Rgb / n) * (Rge / n), where Rgb = 1 for the gene with 
the largest regulatory potential, and the other is based on the increasing of P value. 
Similarity, Rge = 1 for the gene with the largest absolute value of log2 Fold change, and 
the other is based on the increasing of P value. n stands for the number of differentially 
expressed genes. Genes with BETA scores greater than 0 are considered direct JunB 
responsive targets.  
 
BETA activating and repressive function prediction of JunB responsive 
genes. 
Activating/repressive function prediction to determine the activator or repressor role of 
JunB was performed with BETA software (133). Differential expression of genes in 
Junb-deficient CD4+ T cells vs control cells was obtained from RNA-seq data. A 
consensus JunB ChIP-seq peak dataset was obtained from the union of JunB ChIP-seq 
data for Th1 cells and Th17 subsets (GSE86535), as described in previous section. 
Genes were first categorized as non-differential (NON), up- (UP) and down-regulated 
(DOWN), based on their expression profiles. For a given gene, the regulatory potential 
score was calculated with JunB ChIP-seq peaks felling within 10 kb upstream of TSS 
or within this gene body. A higher regulatory potential score represents a greater JunB 
ChIP-seq occupancy near this given gene. Genes are cumulated by the rank based on 
the regulatory potential score from low to high. The distributions of UP and DOWN 
genes were compared to the NON gene distribution. The significance of activating or 
repressive function, as represented by P values, were obtained by Kolmogorov-Smirnov 
test (134). 
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Differential motifs enrichment in direct JunB responsive genes 
Motif scan of targets for known transcription factors around JunB ChIP-seq peaks (200 
bp regions centered on JunB ChIP-seq peak summits) in genomic regions containing 
JunB responsive genes (10 kbp upstream of TSS or within the gene bodies of JunB 
responsive genes) was performed with BETA software (133). Genes were first 
categorized as non-differentially expressed (NON), up- (UP), and down-regulated 
(DOWN) genes, based on their expression profiles. To identify motifs differentially 
enriched in JunB ChIP-seq peaks near JunB responsive genes, the occurring frequency 
of a given motif found in ChIP-seq peaks near up- (UP) or down-regulated (DOWN) 
genes was obtained and compared to the occurring frequency of non-differentially 
expressed (NON) genes. The significance of a differentially enriched motif, represented 
by P value, was measured by the one-tailed t test (133). 
 
Code availability. 





RNA-Seq and ChIP-Seq data have been uploaded to the Gene Expression Omnibus 
with primary accession number GSE172490.  
 
Statistical analysis. 
Unpaired two-tailed Student’s t tests were performed using Prism software (GraphPad). 
P values < 0.05 were considered statistically significant. 
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Fig. 10. Framework schematic for bioinformatics analysis and prediction of 
direct/indirect JunB target genes.  
Bioinformatics software used in each process step were highlighted. Detailed 
parameters and command lines were explained in method and materials section. This 
framework schematic is related to Fig. 22. 
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Chapter 3: Result 
 
Part I. JunB promotes cell survival in CD4+ effector T cells in vitro 
We and others have demonstrated that JunB contributes to differentiation and functions 
of Th2, Th9, Th17 and effector Treg (eTreg) cell subsets (97–103,104). Whether JunB 
regulates common biological functions in diverse CD4+ effector T cell subsets, however, 
is still unclear. Previous studies have shown that deletion of IRF4 and BATF 
upregulated expression of key apoptosis initiators such as Bim and Fas, suggesting that 
IRF4 and BATF may promote cell survival through regulating apoptosis in both CD4+ 
and CD8+ T cells (66, 68, 106, 113, 120, 135). As a major partner of BATF and IRF4, 
JunB may also possess similar biological functions in regulating T cell survival. Indeed, 
our recent study demonstrated that the percentage of apoptotic cells increased in Junb-
deficient eTreg cells in peripheral tissues (102). Thus, JunB might promote cell survival 
when CD4+ T cells are activated by TCR stimulation, regardless of cell subsets. 
To test this hypothesis, I activated naïve CD4+ T cells isolated from Junbfl/fl 
(control) or Junbfl/flCd4cre (Junb-deficient) mice with anti-CD3 and anti-CD28 
antibodies in the presence of cytokines that promote differentiation of Th0, Th1, Th2, 
or Th17 subsets. 96 h after activation, I observed that Junb-deficient CD4+ T cells 
exhibited a significant decrease in the percentage and absolute number of living cells 
under Th1-, Th2- and Th17-polarizing conditions. As in Th0-polarizing conditions, 
most cells died, regardless of the presence or absence of JunB (Fig. 11A). To determine 
whether JunB affects apoptosis, I used two markers for apoptosis - Annexin V and Bim. 
Annexin V staining at 72 h after activation demonstrated an increase of apoptotic cells 
(Annexin V+ Zombie-NIR-) in Junb-deficient CD4+ T cells under Th1-, Th2- and Th17-
polarizing conditions (Fig. 11B). Furthermore, JunB deficiency upregulated Bim under 
all Th-polarizing conditions (Fig. 11C).  
Previous studies have shown that Cre/loxP-mediated gene deletion may result in 
decreased cell viability and abnormal metabolic activity in mammalian cells (136, 137). 
To exclude the possibility that the impaired cell survival in Junb-deficient CD4+ T cells 
may be caused by artificial effects of our Cre/loxP Junb knockout model, I evaluated 
the effects of JunB knockout in activated CD4+ T cells with CRISPR/Cas9-mediated 
gene deletion methods (124). I electroporated naïve CD4+ T cells isolated from wild-
type mice (C57BL/6) with Cas9 proteins and guide RNAs targeting Junb. 72h later, I 
activated cells under Th1-, Th2- and Th17-polarizing conditions. Transduction of a 
guide RNA targeting Junb resulted in an increase of cells deficient for JunB expression 
under all differentiation conditions tested (Fig 12A). Cells exhibiting deficient JunB 
expression also showed significant decreases of cell survival (Fig 12B). These data 
indicate the requirement for JunB in promoting survival in TCR-stimulated CD4+ T 
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cells was not caused by the artificial effects of Cre/loxP knockout model. These results 
indicate that JunB promotes cell survival probably by repressing expression of 
apoptosis initiator Bim across diverse T helper cell subsets in vitro. 
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Fig. 11. JunB is required for survival of TCR-stimulated CD4+ T cells.  
Naïve CD4+ T cells isolated from Junbfl/fl or Junbfl/flCd4cre mice were cultured in 
differentiation conditions for Th0, Th1, Th2, and Th17 cells and were analyzed by flow 
cytometry at indicated time points. (A) Zombie-NIR staining of cells cultured for 96 h. 
Numbers in histograms (left) indicate average percentages of Zombie-NIR- cells. Bar 
graphs show percentages (top right) and absolute numbers (bottom right) of Zombie-
NIR- cells. (B) Zombie-NIR and Annexin-V staining of cells cultured for 72 h. Counter 
plots (left) and the bar graph (right) indicating percentages of Zombie-NIR- Annexin-
V+ cells are shown. (C) Analysis of Bim expression in cells cultured for 72 h. Numbers 
in histograms (left) indicate average percentages of Bim+ cells. Bar graphs (right) show 
median fluorescence intensity (MFI). (A-C) Error bars indicate s.d. (n = 4-6 wells per 
group). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, (unpaired two-tailed 
Student’s test). Data represent two independent experiments. 
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Fig. 12. CRISPR-mediated JunB knockout impaired survival of TCR-stimulated 
CD4+ T cells.  
Naïve CD4+ T cells isolated from C57BL/6 mice were electroporated with Cas9 protein 
together with guide RNA targeting Junb (gJunB) or negative control guide RNA 
(gNTC). After nucleofection, cells were rested in RPMI containing IL-7 for 72 h and 
cultured under Th1-, Th2- and Th17-polarizing conditions. After resting, JunB and 
Zombie-NIR were analyzed by flow cytometry. (A) Flow cytometry analysis of JunB.  
Numbers in histogram plots indicate average percentages of cells exhibiting high or low 
JunB expression levels (JunBhi, JunBlo). (B) Flow cytometry analysis of Zombie-NIR. 
Error bars indicate s.d. (n = 4-6 wells per group). * p < 0.05, ** p < 0.01, *** p < 0.001, 
**** p < 0.0001, (unpaired two-tailed Student’s test). 
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Part II. JunB regulates expression of a subset of lineage-specific genes in 
vitro 
The role of JunB in Th1 and Th2 differentiation remains unclear and even controversial. 
Two independent studies reported that expression of IFN-γ was upregulated or 
unaltered in Junb-deficient Th1 cells (99, 101). Similarly, expression of IL-4 was 
reportedly downregulated or unaltered in Junb-deficient Th2 cells (99, 101).  
To re-investigate the role of JunB in Th1 and Th2 differentiation, I activated naïve 
CD4+ T cells isolated from control and Junb-deficient mice under Th1-, Th2-, and 
Th17-polarizing conditions and examined the expression of lineage-specifying 
transcription factors and signature cytokines by flow cytometry analysis. Consistent 
with previous studies, expression of T-bet and IFN-γ was significantly up-regulated in 
Junb-deficient cells under Th1- and Th17-polarizing conditions (Fig. 13A, B). On the 
other hand, the concentration of IFN-γ in culture medium from Junb-deficient cells was 
not altered in Th1-polarizing conditions, but it was increased in Th17-polarizing 
conditions (Fig. 13C). It is likely that the frequency of IFN-γ-expressing cells was 
increased, but the absolute number was not altered due to defective survival of JunB-
deficient cells under Th1-polarizing conditions.  
Under Th2-polarizing conditions, flow cytometry analysis showed that expression 
of Th2-lineage-specifying transcription factor, GATA3, was not affected, but expression 
of Th2 signature cytokines IL-4 and IL-13 was down-regulated in Junb-deficient Th2 
cells (Fig. 13A, B). Furthermore, concentration of IL-13 was significantly lower in 
culture medium from Junb-deficient Th2 cells (Fig. 13C). Thus, JunB deletion in CD4+ 
T cells upregulated and downregulated the expression of Th1- and Th2-lineage specific 
cytokine expression, respectively.  
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Fig. 13. JunB-dependent regulation of the lineage-specifying transcription factor 
and signature cytokines in CD4+ effector T cells.  
Naïve CD4+ T cells isolated from Junbfl/fl or Junbfl/flCd4cre mice were cultured under the 
indicated polarizing conditions for 72 h. Flow cytometry analysis of expression of 
lineage-specifying transcription factors (A) and cytokines (B) for Th1, Th2, and Th17 
cells. Enzyme-linked immunosorbent assay (ELISA) analysis (C) of concentrations of 
cytokines for medium of Th1, Th2, and Th17 cells. ND, not detectable. (A-C) Error 
bars indicate s.d. (n = 4-6 wells per group). * p < 0.05, ** p < 0.01, *** p < 0.001, **** 
p < 0.0001, (unpaired two-tailed Student’s test). Data represent two independent 
experiments. 
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Part III: JunB modulates metabolic programs only in Th2, but not in Th1 
and Th17 
JunB-interacting partners, BATF and IRF4, regulate metabolic activities in both CD4+ 
and CD8+ T cells (68, 74, 106, 113). Moreover, a recent study further demonstrated that 
IRF4 directs the metabolic programs shifting from oxidative phosphorylation 
(OXPHOS) toward glycolysis in CD8+ effector T cells during immune response (68). 
To investigate the role of JunB in regulating metabolic programs of CD4+ T cells, I 
activated control and Junb-deficient CD4+ T cells under differentiation conditions for 
Th1, Th2, and Th17 cells and analyzed oxidative phosphorylation and aerobic 
glycolysis activity using a seahorse analyzer. Under both Th1- and Th17-polarizing 
conditions, extracellular acidification rates (ECAR) and oxygen consumption rates 
(OCR) were not affected by loss of JunB (Fig. 14A, B). However, under Th2-polarizing 
conditions, basal ECAR were significantly lower in Junb-deficient CD4+ T cells than 
in controls, although the maximum glycolytic capacity (ECAR in the presence of 
oligomycin) was comparable (Fig. 14A). As OCR were not affected (Fig. 14B), the 
OCR/ECAR ratio in Junb-deficient CD4+ T cells increased under Th2-polarizing 
conditions, suggesting a metabolic program shifting from glycolysis activity to 
oxidative phosphorylation in Junb-deficient Th2 cells. These results indicate that JunB 
is required for promoting glycolysis and metabolic reprogramming of Th2 cells, but not 
of Th1 or Th17 cells.  
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Fig. 14. Metabolic reprogramming in Junb-deficient CD4+ T cells.  
Naïve CD4+ T cells isolated from Junbfl/fl or Junbfl/flCd4cre mice were cultured under 
Th1-, Th2-, and Th17-polarizing conditions. After 48 h, metabolic activity was 
measured using a seahorse analyzer. (A) Extracellular acidification rate (ECAR) in cells 
cultured under differentiation conditions for Th1, Th2, and Th17 cells. During ECAR 
measurement, cells were sequentially treated with glucose, oligomycin, and 2-Deoxy-
D-glucose (2-DG). (B) Oxygen consumption rate (OCR) in cells cultured under 
differentiation conditions for Th1, Th2, and Th17 cells. During OCR measurement, 
cells were sequentially treated with oligomycin, fluorocarbonyl cyanide 
phenylhydrazone (FCCP), rotenone and antimycin A. (A, B) Error bars indicate s.e.m 
(n = 6 wells per group). * p < 0.05, (unpaired two-tailed Student’s test). Data represent 
two independent experiments.  
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Part IV. JunB promotes cell survival of CD4+ effector T cells in vivo. 
My in vitro data demonstrated that JunB is not only required for survival of various 
CD4+ effector T subsets under TCR stimulation but also required for expression of a 
subset of genes encoding effector molecules such as IL-4 and IL-13. Next, I sought to 
determine the in vivo role of JunB in CD4+ effector T cells using the adoptive transfer 
technique, which allows us to track TCR transgenic CD4+ T cells specific to a single 
antigen at different time points throughout the course of an immune response (138).  
First, to analyze expression of JunB in CD4+ T cells activated in vivo, I isolated 
naïve CD4+ T cells from OT-II transgenic mice (hereafter referred to as OT-II cells), in 
which all T cells harbor a allele of TCR and specifically respond to peptide derived 
from ovalbumin 323 – 339 epitope (OVA323-339) (139, 140). I then transferred OT-II 
cells into congenic mice on a CD45.1+ background and immunized the recipient with 
OVA323-339 peptide in Complete Freund’s Adjuvants (CFA) 1 day later (Fig. 15A). At 3, 
5, and 7 days post immunization (dpi), I analyzed expression levels of CD44 and JunB 
in CD4+ T cells isolated from inguinal lymph nodes. Almost all transferred OT-II cells 
(>99%) became activated (CD44 high, CD44hi) at 5 dpi (Fig. 15B), and expression of 
JunB was induced in more than half of activated OT-II cells and was maintained until 
7 dpi (Fig. 15C).  
I next sought to determine the effects of JunB deletion on the differentiation of 
CD4+ T cell in mice immunized with various adjuvants. To this end, I co-transferred 
naïve OT-II cells isolated from Junbfl/fl OT-II (control OT-II) or Junbfl/flCd4cre OT-II 
(Junb-deficient OT-II) mice (CD45.2+) together with congenic OT-II cells (CD45.1+ 
45.2+) at a 2:1 ratio into congenic recipient mice (CD45.1+). One day later, I immunized 
mice with OVA323-339 peptides together with either CFA, LPS, or papain (Fig. 16A) (114, 
141, 142). In all immunization conditions tested, accumulation of Junb-deficient OT-II 
cells at 5 dpi was severely impaired (Fig. 16B-D). Furthermore, the frequency of 
apoptotic cells (Annexin V+ Zombie-NIR-) tended to be higher in Junb-deficient OT-II 
cells than controls, although the difference was not statistically significant (Figure. 
17B). Percentages of cells expressing a pro-apoptotic molecule, Bim, were significantly 
higher in Junb-deficient OT-II cells (Figure. 17C). I also analyzed the effect of JunB 
deletion on the frequency of cytokine-expressing cells. CFA, LPS, and papain mainly 
induced accumulation of OT-II cells expressing cytokines for Th17 (IL-17A), Th1 
(IFN-γ), and Th2 cells (IL-4/13), respectively (Fig. 16E-G). Consistent with previous 
reports (99–101), the percentage of IL-17-expressing cells in mice immunized with 
CFA was significantly lower in Junb-deficient OT-II cells than in controls (Fig. 16E). 
In contrast, the percentage of IFNγ-expressing cells in Junb-deficient OT-II cells was 
increased in mice immunized with LPS (Fig. 16F). Both the percentages of IL-4- and 
IL-13-expressing cells and the expression level of IL-4 and IL-13 were comparable 
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between Junb-deficient and control OT-II cells (Fig. 16G). These data indicate that 
JunB promotes accumulation of antigen-primed CD4+ T cells, regardless of the context 
of inflammation and that JunB has a repressive effect on IFN-γ under LPS-induced 
inflammation, which is consistent with our in-vitro findings. 
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Fig. 15. JunB is homogeneously expressed in antigen-primed CD4+ T cells in 
vivo.  
2 x 106 naïve OT-II cells (CD45.1+CD45.2+) were transferred to congenic recipient 
mice (CD45.1+), followed by immunization with OVA323-339 peptides emulsified in 
CFA. At the indicated days post-immunization (dpi), cells were harvested from inguinal 
lymph nodes and analyzed. (A) Immunization scheme. i.v. intravenous injection, s.c. 
subcutaneous injection. (B) Flow cytometry analysis of CD44 in transferred 
(CD45.1+CD45.2+) OT-II cells and recipient (CD45.1+) CD3+CD4+ T cells isolated 
from inguinal lymph nodes at indicated days post-immunization (dpi). Representative 
histograms (left) are shown (transferred OT-II cells: red lines, host CD4+ T cells: blue 
lines). Numbers in histograms (left) indicate average percentages of CD44hi cells. Bar 
graphs (right) indicate the percentage of CD44hi cells in transferred OT-II cells and 
recipient CD3+CD4+ T cells. (C) Flow cytometry analysis of JunB expression in 
transferred OT-II cells (CD3+CD4+CD45.1+CD45.2+) and recipient naïve CD4+ T cells 
(CD3+CD4+CD45.1+CD44lo) at the indicated dpi. Representative histograms (left) are 
shown (OT-II: red lines, host naïve CD4 T cells: blue lines, mouse IgG control: grey 
lines). Numbers in histograms (left) indicate average percentages of JunB+ cells. Bar 
graphs (right) indicate the median florescence intensity (MFI) of JunB in transferred 
OT-II cells and recipient CD3+CD4+ T cells. (B-C) Error bars indicate s.d. (n =4). Error 
bars indicate s.d. (n =3). **** p < 0.0001, (unpaired two-tailed Student’s test). 
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Fig. 16. JunB promotes accumulation of antigen-primed CD4+ T cells in vivo.  
Naïve Junbfl/fl OT-II or Junbfl/flCd4cre OT-II cells (CD45.2+) were co-transferred with 
congenic wild-type OT-II cells (CD45.1+CD45.2+) at a 2:1 ratio into congenic recipient 
mice (CD45.1+). One day later, mice were immunized with OVA323-339 peptides 
emulsified in CFA or mixed with LPS or papain. At 5 dpi, cells were isolated from 
draining lymph nodes and analyzed by flow cytometry. (A) Immunization scheme. i.v. 
intravenous injection, s.c. subcutaneous injection, i.n. intranasal injection. (B-D) 
Expression of CD45.1 and CD45.2 in CD3+CD4+ T cells isolated from mice immunized 
with CFA (B), LPS (C), and papain (D). Representative dot plots are shown (left). Bar 
graphs (right) show the ratio of Junbfl/fl OT-II or Junbfl/flCd4cre OT-II cells (CD45.2+) vs 
co-transferred OT-II cells (CD45.1+CD45.2+). inLN, inguinal lymph nodes, medLN, 
mediastinal lymph nodes. (E-G) Flow cytometry analysis of IL-17A and (E), IFN-γ (F) 
and IL-4/13 expression (G) in OT-II cells (CD3+CD4+CD45.2+) isolated from mice 
immunized with CFA (A), LPS (B), and papain (C). Representative dot plots are shown 
(left). Bar graphs (right) indicate the percentage of cells expressing IL-17A (E), IFN-γ 
(F), IL-4/13 and the MFI of IL-4/13 (G) in Junbfl/fl OT-II or Junbfl/flCd4cre OT-II cells. 
MFI. Median fluoresce intensity. (B-G) Error bars indicate s.d. (n = 4-6 mice per group). 
* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, (unpaired two-tailed Student’s 
test). Data represent two independent experiments. 
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Fig. 17. JunB is essential for inhibition of apoptosis as well as Bim expression in 
antigen-primed CD4+ T cells in vivo.  
2 x 106 Junbfl/fl OT-II or Junbfl/flCd4cre OT-II cells (CD45.2+) were transferred to 
congenic recipient mice (CD45.1+), followed by immunization with OVA323-339 peptides 
emulsified in CFA. At the 3 days post-immunization (dpi), cells were harvested from 
inguinal lymph nodes and analyzed. (A) Immunization scheme. i.v. intravenous 
injection, s.c. subcutaneous injection. (B-C) Expression of Zombie-NIR and AnnexinV 
(B), and Bim and FasL (C) in total CD3+CD4+CD45.2+ cells isolated from draining 
lymph nodes, analyzed by flow cytometry. inLN, inguinal lymph nodes. (B-C) 
Representative dot plots (left) and bar graphs (right). Error bars indicate s.d. (n =4-6 
mice per group). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, (unpaired 
two-tailed Student’s test). (B-C) Data represent two independent experiments. 
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Part V. JunB promotes lymphopenia-induced CD4+ T cell homeostatic 
proliferation in vivo 
My data suggested that JunB is required for the accumulation of CD4+ effector T cells 
induced upon immunization in an antigen-dependent manner. Next, I investigated 
whether JunB is also required for accumulation of CD4+ effector T cells induced in an 
antigen-independent manner using a lymphopenia-induced homeostatic proliferation 
model (143). In mouse or human, lymphopenia is a low-T-cell number symptom that is 
usually caused by genetic disorder or HIV infection. When hosts recover from 
lymphopenic conditions, excessive nutrients, antigen:MHC complex, and cytokines 
create a special signal niche that drive naïve CD4+ T cells undergo a rapid proliferation 
to reconstitute the T cell compartment, which results in activation of naïve CD4 T cells 
in an antigen-independent manner (144). To test whether JunB is required for 
lymphopenia-induced CD4+ T cell proliferation, I co-transferred naïve CD4+ T cells 
isolated from Junbfl/fl (control) or Junbfl/flCd4cre (Junb-deficient) mice (CD45.2+) 
together with congenic naïve CD4+ T cells (CD45.1+) at a 1:1 ratio into congenic Rag1-
/- recipient mice (Fig. 18A). At 14 days post transfer, the accumulation of Junb-deficient 
CD3+CD4+ T cells was severely impaired in spleens and mesenteric lymph nodes – 
where transferred naïve CD4+ T cells receive antigen stimulation and proliferate 
(Fig.18B, C). This data indicates that JunB is required for accumulation of  
lymphopenia-induced CD4+ effector T cells.   
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Fig. 18. JunB promotes lymphopenia-induced accumulation of CD4+ effector T 
cells in vivo.  
Naïve CD4+ T cells from Junbfl/fl or Junbfl/flCd4cre mice (CD45.2+) were co-transferred 
with naïve CD4+ T cells from congenic wild-type mice (CD45.1+CD45.2+) at a 1:1 ratio 
into congenic recipient Rag1-/- mice (CD45.1+). 14 days later, cells were isolated from 
spleens and mesenteric lymph nodes and analyzed by flow cytometry. (A) Adoptive 
transfer scheme. i.v. intravenous injection. (B-C) Expression of CD45.1 and CD45.2 in 
CD3+CD4+ T cells isolated from spleen (B) and mesenteric lymph nodes (C) of Rag1-/- 
mice received adoptive transfer were analyzed by flow cytometry. Representative dot 
plots are shown (left). Bar graphs (right) show the ratio of Junbfl/fl or Junbfl/flCd4cre 
CD3+CD4+ T cells (CD45.2+) vs co-transferred CD3+CD4+ T cells (CD45.1+).  (B-C) 
Error bars indicate s.d. (n = 4-6 mice per group). * p < 0.05, ** p < 0.01, *** p < 0.001, 
**** p < 0.0001, (unpaired two-tailed Student’s test).  
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Part VI. Bioinformatics study: JunB-dependent transcriptional regulation 
in CD4+ effector T cells 
 
JunB regulates common and lineage specific transcriptional programs 
among distinct CD4+ effector T cell subsets 
We and others have identified that JunB regulates many effector genes during Th17 
differentiation such as Il17a, Il17f, Il23r and Il21 (99–101). My data further 
demonstrated that JunB regulates expression of IFN-γ and IL-4/13 during Th1 and Th2 
cell differentiation, respectively. To further understand JunB-dependent transcriptional 
regulation in various CD4+ effector T cell subsets, I performed RNA-seq analysis of 
CD4+ T cells activated in vitro for 48 h under Th0-, Th1-, and Th2-poralizing conditions. 
Expression of 266 genes in Th0 cells, 355 genes in Th1 cells, and 514 genes in Th2 
cells was significantly affected by the loss of JunB (Fig. 19 A-C).  
In Junb-deficient Th1 cells, Ifng, Il12rb2, Il2ra, and Eomes were upregulated, but 
Ifngr2 was downregulated (Fig. 19B). In Junb-deficient Th2 cells, Il4ra and Il13 were 
upregulated and downregulated, respectively (Fig. 19C). Loss of JunB did not affect 
expression of the lineage-specifying transcription factors, Tbx21 and Gata3, in Th1 and 
Th2 cells, respectively (Fig. 19B, 19C). Combined with 1,138 differentially expressed 
genes identified in the previously reported RNA-seq data of Junb-deficient Th17 cells 
(101), I identified 1,755 genes that were upregulated or downregulated by the loss of 
JunB in T helper cell differentiation (Fig. 19E). Most of those genes were found in a 
specific Th subset (85 genes specific to Th0 cells, 157 specific to Th1 cells, 247 specific 
to Th2 cells, 884 genes to Th17), while only 28 genes were found in all T helper cells 
tested (Fig. 20 E). Notably, under all Th-polarizing conditions tested, Bcl2l11 (encoding 
Bim) and TCR-induced genes (Sell, Ikbke, Thy1) were upregulated (Fig. 19E).  
Enriched pathway analysis revealed that TCR-mediated apoptosis, IL-2, and TCR 
signaling pathways were significantly affected by loss of JunB (Fig. 20A-D). Pathways 
involved in cell proliferation and cellular metabolism were not detected in the pathway 
analysis, but expression of some genes encoding glycolytic enzymes was affected by 
deletion of JunB. Eno3 (encoding enolase 3) was upregulated under all Th-polarizing 
conditions tested (Fig. 19E), while Pgm2l1 (encoding glucose 1,6-bisphosphate 
synthase) was downregulated only under Th2 polarizing conditions (Fig. 19B). Thus, 
JunB is essential for control of a subset of genes induced by TCR and IL-2 signaling, 
including Bcl2l11, and it also regulates various cytokines and cytokine receptors that 
are expressed in specific CD4+ effector T subsets. 
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Fig. 19. JunB-dependent transcriptional regulation in T helper cell differentiation.  
Naïve CD4+ T cells isolated from Junbfl/fl or Junbfl/flCd4cre mice were cultured under 
Th0-, Th1- and Th2-polarizing conditions for 48 h and subjected to RNA-seq analysis. 
Differentially expressed genes in Junb-deficient CD4+ T cells vs control cells (log2 fold 
change > 0.5, p value < 0.05, base mean > 100 TPM (normalized transcript per kilobase 
million)) were identified in each Th-polarizing condition. (A-D) Scatter plots represent 
genes differentially expressed in Junb-deficient CD4+ T cells vs control cells under 
differentiation conditions for Th0 (A), Th1 (B), and Th2 (C) cells. RNA-seq data for 
Junb-deficient CD4+ T cells cultured under Th17-polarizing conditions were from GSE 
98414. (D) Genes considered significantly upregulated or downregulated are 
highlighted in red and blue, respectively. Genes with insignificant changes are 
highlighted in grey. On each plot, left top and right bottom numbers indicate numbers 
of upregulated or downregulated genes, respectively. (E) Venn diagrams show the 
overlap of differentially expressed genes identified in Junb-deficient CD4+ T cells vs 
control cells under different Th-polarizing conditions. 
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Fig. 20. JunB regulates IL-2 signaling, TCR signaling and apoptosis pathways.  
EnrichR pathway analysis of genes differentially expressed in Junb-deficient CD4+ T 
cells vs control cells under differentiation conditions for Th0 (A), Th1 (B), and Th2 
(C). RNA-seq data for Junb-deficient CD4+ T cells cultured under Th17-polarizing 
conditions were from GSE 98414 (D). Pathways related to IL-2 signaling, TCR 
signaling, and apoptosis are highlighted.  
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JunB directly binds and regulates genes involved in differentiation and 
functions of diverse CD4+ effector T cells 
We and others have shown that JunB colocalizes with BATF and IRF4 at various gene 
loci containing AICE motifs and thereby directly regulates expression of genes 
important for Th17 cells (78, 79, 100, 101). However, the mechanism of JunB-
dependent transcriptional regulation in differentiation of other CD4+ effector T cells 
remains largely uncharacterized. To address this, I investigated genome-wide JunB-
DNA binding in cells activated under Th1-polarizing conditions in vitro using 
chromatin immunoprecipitation sequencing (ChIP-seq) analysis with antibodies to 
JunB, BATF and IRF4 and compared with ChIP-seq data that we previously obtained 
from Th17 subsets (100). In both Th1 and Th17 cells, more than 60% of all the three 
transcription factors (TF) peaks fell in regions within 10kbp upstream of transcription 
starting sties (TSS) or located in the gene bodies (Fig. 21A, B and Table 4). This 
suggests that JunB, BATF and IRF4 regulate expression of their target gens largely 
through binding to regions proximal to their target genes in both Th1 and Th17 cells.  
Next, I further integrated ChIP-seq data for JunB, BATF, and IRF4 in Th1 and 
Th17 (100) and RNA-seq data for Junb-deficient Th1, Th2, and Th17 subsets (101). I 
first combined ChIP-seq data obtained from Th1 and Th17 cells to generate a consensus 
ChIP-seq peak set for JunB, BATF, and IRF4. I then associated this ChIP-seq peak set 
or AP-1 binding motif with genomic regions containing “JunB-responsive genes” 
(genes differentially expressed between Junb-deficient and control CD4+ T cells in 
RNA-seq data). I detected JunB ChIP-seq peaks and AP-1-binding motifs in 10 kbp 
upstream of transcription starting site or directly within gene bodies of most JunB-
responsive genes, regardless of whether they were upregulated or downregulated by 
deletion of JunB in Th1, Th2 and Th17 subsets. With the analysis using binding and 
expression target (BETA) software, I identified genes that have a greater likelihood of 
direct regulation by JunB. These genes I considered “direct JunB responsive genes” 
(BETA > 0, Fig. 22A). Direct JunB responsive genes include many genes important for 
differentiation and function of CD4+ effector T subsets, including cytokines, 
chemokines, their receptors, exhaustion related molecule, and Bcl2l11, while indirect 
JunB responsive genes included Il6ra, of which protein products are involved in many 
CD4+ effector T cell subsets differentiation (Fig. 22A) (145).  
I next examined whether the JunB ChIP-seq peaks overlapped with BATF and 
IRF4 ChIP-seq peaks in genomic regions containing direct JunB responsive genes. 
Overlapping ChIP-seq peaks for JunB, BATF, and IRF4 were detected in genomic 
regions for more than 70% of direct JunB responsive genes (Fig. 22B). Thus, JunB 
cooperatively works with BATF and IRF4 to directly regulate the transcriptional 
programs in Th1, Th2, and Th17 cells. 
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Lastly, I performed Enrichr pathway analysis to further reveal the function 
difference between direct JunB responsive genes that were or were not co-bound by 
BATF and IRF4. Consistent with the pathway analysis of genes regulated by JunB (Fig. 
20), TCR-mediated apoptosis, IL-2, and TCR signaling pathways were significantly 
enriched in direct JunB responsive genes that were co-bound by BATF and IRF4 (Fig. 
23A-C). In the other hand, no specific biological pathway was significantly enriched in 
genes  direct JunB responsive genes that were not bound by BATF and IRF4 (Fig. 
23A-C). However, genes with only JunB peaks contain genes required for Th1 
differentiation such as Eomes and Ifngr2 (Fig. 23A) (146) or Myo6 – a gene encoding 
the actin-based motor proteins that move cargo towards the minus ends of actin 
filaments (Fig. 23B) (147). Together, this data suggest that JunB may regulate a subset 
of gene expression and controls different biological functions during Th1 and Th2 
differentiation independently of BATF and IRF4.  
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Fig. 21. Profiles of JunB, BATF and IRF4 binding peaks in Th1 and Th17 cells  
JunB, BATF and IRF4 ChIP-seq data were obtained from cells cultured under Th1-
polarizing conditions for 48h (A) or from Th17 cells (GSE86535) (B). Histograms show 
frequencies of each transcription factor (TF) binding peaks in different types of DNA 
regions. Numbers on histogram indicate the total percentages of TF binding peaks 
felling within 10kbp upstream of transcription starting site or within gene bodies, the 
boundaries of which of a given gene are defined by transcription starting sites and 
termination sites. TSS, transcription starting site; UTR, untranslated region; TTS: 
transcription termination site. 
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Table 4. A detailed list of profiles of JunB, BATF and IRF4 binding peaks 
 
 Th1 Th17  
JunB BATF IRF4 JunB BATF IRF4 
5-10 kbp upstream of TSS 4.36 4.48 4.72 4.36 4.34 4.51 
< 5 Kbp upstream of TSS 8 8.67 13.8 7.9 6.47 9.1 
5' UTR 0.14 0.16 0.36 0.16 0.11 0.24 
1st Exon 0.27 0.35 0.59 0.28 0.26 0.45 
Other Exon 2.11 2.18 2.32 2.21 2.48 2.49 
Intron 47.3 48.93 47.95 45.07 44.9 46.24 
TTS 1.3 1.39 1.65 1.38 1.34 1.47 
3' UTR 1.02 1.08 1.14 1.11 1.06 1.19 
Intergenic regions 33.1 30.15 19.11 35.07 38.01 30.83 
 
ChIP-Seq analysis for JunB, BATF and IRF4 binding sites in Th1 and Th17 (GSE86535) 
were further categorized based on their genome annotations. The numbers in the table 
indicate the percentage of ChIP-seq peaks for each transcription factor that locates 
within the specified DNA regions. This table is related to Fig. 23. TSS, transcription 
starting site; UTR, untranslated region; TTS: transcription termination site. 
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Fig. 22. JunB directly regulates expression of various genes in CD4+ effector T 
cell subsets.  
Differentially expressed genes (JunB responsive genes) in Junb-deficient CD4+ T cells 
vs control cells were obtained from RNA-seq analysis (as in Fig. 21). A consensus JunB 
ChIP-seq peak dataset was obtained from the union of JunB ChIP-seq data for Th1 cells 
and Th17 subsets (GSE86535). AP-1-binding motifs were scanned across the mouse 
genome (ver. mm10). Data of RNA-seq, JunB ChIP-seq, and AP-1-binding motif 
analyses were merged and are shown in the heatmap. BETA analysis data (a higher 
BETA rank score represents a greater likelihood of direct regulation by JunB) is also 
shown in the heatmap. JunB-responsive genes that had BETA scores greater than 0 
were defined as “direct JunB responsive genes”. In contrast, JunB responsive genes that 
had BETA score equal to 0 were defined as “indirect JunB responsive genes”. (B) Pie 
charts show the percentage of direct JunB responsive genes that did or did not have 
overlapping peaks for JunB, BATF, and IRF4. Overlapping peaks were obtained by 
comparing ChIP-seq data of JunB with that of BATF and IRF4. The consensus ChIPseq 
peak sets for BATF and IRF4 were obtained from the union of ChIP-seq data for Th1 
cells and Th17 subsets (GSE86535). 
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Fig. 23. The function difference between direct JunB responsive genes that co-
localized by JunB, BATF and IRF4 and those that are bound with only JunB.  
EnrichR pathway analysis of direct JunB responsive genes in cells cultured under 
differentiation conditions for Th1 (A), Th2 (B), and Th17 (C). Histogram graphs show 
pathways enriched in genes with overlapping peaks for Junb, BATF and IRF4 (left) or 
pathways enriched in genes with JunB peaks only (right). Pathways related to IL-2 
signaling, TCR signaling, and apoptosis are highlighted.  
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JunB potential interacts with various family proteins to acts as both a 
repressor and activator in CD4+ effector T cells 
My RNA-seq analysis revealed that JunB acts as both an activator and repressor in 
regulating gene expression in CD4 T cell differentiation. To further address this, I 
performed activating/repressive function prediction with BETA software (133), which 
allows us to integrate RNA-seq and ChIP-seq data and examine whether JunB 
preferably binds to target genes that are up- or down-regulated by JunB. This analysis 
revealed that although the occupancy of JunB ChIP-seq peaks in genomic regions 
containing genes that are upregulated by JunB are slightly higher than those containing 
genes that are down-regulated by JunB, the difference is not statistically significant (Fig. 
24). Thus, JunB can bind to various genes in order to promote and repress gene 
expression.  
How JunB performs this “Janus” regulation is still unclear. One hypothesis is JunB 
interacts with different family proteins to extend its regulatory capacity. Previous 
studies suggested that AP-1 heterodimer can interact with other transcription factors 
such as NFAT family proteins with their dimerized leucine zipper domain (148). Recent 
studies also suggested Ets family proteins interact with BATF and JunB in regulating 
function and differentiation in Th17 and Th9 cells (88, 98). To identify potential JunB 
interacting partners, I performed motif scan with BETA software to reveal differentially 
enriched motifs in JunB ChIP-seq peaks near the genomic regions containing genes 
regulated by JunB (10kbp upstream of TSS or within the gene bodies of JunB 
responsive genes). As in line with previous studies, motif of Etv3, a Ets family protein, 
was significantly enriched in JunB ChIP-seq peaks near JunB up- and down-regulated 
genes over those that are not regulated by JunB, regardless of cell subsets (Fig. 25). I 
also obtained motifs of Rsf2 and Osr2, members of Rfx and β-β-α-Zinc finger domain 
families, respectively, differentially enriched in JunB responsive genes in Th1, Th2, and 
Th17 cells (Fig. 25). Thus, JunB potentially interacts with various family proteins to 
perform its activating and repressive regulatory functions in various CD4+ effector T 




Fig. 24. JunB acts as both an activator and repressor in providing direct 
transcriptional regulation on gene expression  
BETA activating/repressive function prediction of JunB responsive genes in Th1, Th2, 
and Th17 cells. Differentially expressed genes between Junb-deficient CD4+ T cells 
and control cells was from RNA-seq data (JunB responsive genes, as in Fig. 21). A 
consensus JunB ChIP-seq peak dataset was obtained from the union of JunB ChIP-seq 
data for Th1 cells and Th17 subsets (GSE86535). Genes were first categorized as non-
differential (NON), up- (UP), and down-regulated (DOWN) genes, based on their 
expression profiles. For a given gene, the regulatory potential score was calculated 
based on JunB ChIP-seq peaks felling within 10 kb upstream of TSS or within this gene 
body. A higher regulatory potential score represents a greater JunB ChIP-seq 
occupancy near this given gene. Genes are cumulated by the rank based on the 
regulatory potential score from low to high. Cumulative regulatory potential scores of 
up- (UP) and down-regulated (DOWN) genes were represented by the red and purple 
lines, respectively. Cumulative regulatory potential scores of non-differentially 
regulated (NON) genes was represented as the dashed line, serving as background. P 
values that represent the significance were obtained by comparing the UP or DOWN 
group distributions to the NON group with Kolmogorov-Smirnov test.  
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Fig. 25. Motifs are differentially enriched in JunB responsive genes  
Motif scan of known transcription factors was performed with BETA software for 
identifying motifs in genomic regions containing JunB ChIP-seq peaks near JunB 
responsive genes (10kbp upstream of TSS or within the gene bodies of JunB responsive 
genes). Only 200bp regions centered on the peak summits were used for motif scan. To 
identify motifs differentially enriched in genomics regions containing JunB responsive 
genes, genes were first categorized as non-differentially expressed (NON), up- (UP), 
and down-regulated (DOWN) genes. The occurring frequency of a given motif found 
in ChIP-seq peaks near up- (UP) or down-regulated (DOWN) genes was obtained and 
compared to the occurring frequency of non-differentially expressed (NON) genes. The 
significance of a differentially enriched motif, represented by P value, was measured 
by the one-tailed t test. 
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Chapter 4: Discussion 
Part I. Thesis overview 
Here I demonstrate that JunB is required for accumulation of various CD4+ effector T 
cells both in vitro and in vivo. Accumulation of antigen-primed CD4+ T cells was 
significantly impaired by deletion of JunB in mice immunized with LPS, papain, or 
CFA, which predominantly induced Th1, Th2, and Th17 responses, respectively. 
Commensurate with this, viability of TCR-stimulated naïve CD4+ T cells was decreased 
by deletion of JunB under in vitro differentiation conditions for Th1, Th2, and Th17 
cells. One of the key functions of JunB is to inhibit apoptosis in TCR-stimulated naïve 
CD4+ T cells, as Junb-deficient CD4+ T cells are more sensitive to TCR-induced 
apoptosis with a concomitant increase of expression of a pro-apoptotic molecule, Bim. 
Common target genes for JunB in differentiation of various CD4+ effector T subsets 
include genes associated with TCR and IL-2 signaling, such as Bcl2l11 (encoding Bim), 
Sell (encoding CD62L), Ikbke (encoding IκBKε) and Thy1 (encoding CD90). JunB 
bound directly to loci of those genes and negatively regulated their expression in Th1, 
Th2, and Th17 cells. Dysregulation of those genes likely contributes to defective 
accumulation of TCR-stimulated CD4+ effector T cells. As deletion of Junb also greatly 
sensitizes thymus-derived Treg cells to TCR-induced apoptosis (102), TCR-stimulated 
CD4+ effector and regulatory T cells share a common requirement for JunB-dependent 
negative modulation of the TCR-induced apoptosis signal. 
 JunB also regulates expression of a variety of genes in a context-dependent 
manner. As our lab and others have reported, JunB promotes expression of Rorc, Il17a 
and Il17f (100, 101) in Th17 cells and negatively regulates Ifng in Th1 and Th17 cells 
(101). In this study, my RNA-seq analysis further clarified the role of JunB in a 
transcriptional program for CD4+ effector T differentiation. In Th1-polarizing 
conditions, expression of Th1 signature genes, not only Ifng, but also Il12rb2, Il2ra and 
Eomes, was promoted by JunB deletion. In Th2-polarizing conditions, Il4ra and Il13 
were upregulated and downregulated, respectively, by JunB deletion. However, JunB 
deletion did not affect induction of the lineage-specifying transcription factors, T-bet 
and GATA3, in Th1 and Th2 cells, respectively. Thus, JunB is not required for induction 
of lineage-specifying transcription factors, but it regulates expression of some lineage-
specific molecules in Th1 and Th2 differentiation.  
 In addition to previously identified JunB target genes in Th17 differentiation, 
I have identified a large number of novel JunB targets in Th1 and Th2 differentiation. 
Many JunB target genes were identified in a specific CD4+ effector T subset, which 
might be partly due to subset-specific chromatin landscapes. My integrated analysis of 
ChIP-seq and RNA-seq data identified direct and indirect targets for JunB in CD4+ 
effector T subsets. Remarkably, direct JunB targets included molecules that have been 
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functionally characterized in immune responses, including cytokines, chemokines, and 
their receptors. BATF and IRF4 co-bound about 70% of those genes, confirming a 
critical role for JunB in BATF and IRF4-dependent transcriptional control in CD4+ 
effector T cell differentiation. 
Deletion of JunB decreased expression of a glycolysis-related gene, Pgm2l1, in 
Th2-, but not in Th1- and Th17-polarizing conditions. This might account for impaired 
aerobic glycolysis in Junb-deficient cells under Th2-polarizing conditions. In contrast, 
although another glycolysis-related gene, Eno3, was upregulated by deletion of JunB 
in all Th-polarizing conditions tested, aerobic glycolysis in Th1 and Th17 cells was not 
significantly affected by deletion of JunB. This is in contrast to the critical function of 
IRF4 in regulating glycolytic enzyme genes in CD4+ and CD8+ effector T cell 
differentiation. These data suggest that JunB regulates metabolic reprogramming that 
is necessary for specific T helper subsets.  
My data demonstrate that JunB is required for survival of Th1, Th2, Th17 and 
probably other CD4+ effector T cells. However, in some situations, CD4+ effector T 
cells can be generated normally, independently of JunB. For example, loss of JunB does 
not affect the frequency of gut-resident homeostatic Th17 cells (100, 101). We still do 
not know what determines the necessity of JunB in CD4+ effector T cell generation, but 
JunB may not be needed for accumulation of cells that are activated by a weak TCR 
signal or in a less inflammatory environment. 
 In conclusion, my thesis provides substantial evidence that JunB plays a 
critical role not only in Th17, but also in Th1 and Th2 responses both in vitro and in 
vivo. My data clarify genome-wide transcriptional targets for JunB in those T helper 
cells (Fig. 26). Collectively, these data shed light on JunB-dependent transcriptional 
regulatory mechanisms in differentiation of various CD4+ effector T cells.   
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Fig. 26. JunB-dependent regulatory mechanism in CD4+ effector T cells  
JunB directly regulates genes involved in TCR, IL-2 signaling and apoptosis across 
diverse T helper cell subsets. At each cell subset, JunB provides a direct regulation on 
expression of lineage specific genes. Genes up- and down-regulated by JunB deletion 
in CD4+ T cells are marked as red and blue, respectively. 
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Part II. JunB inhibits Th1 differentiation but promotes Th2 cell functions 
JunB plays different roles between Th1 and Th2 cells. JunB is not required for Th1 
differentiation and seems to act as a repressor for Th1 program, as deletion of JunB 
upregulates expression of T-bet and IFN-γ (Fig. 13). RNA-seq analysis revealed more 
Th1-linegae specific genes, including Eomes, Il12rb2, and Il2ra,whose expression was 
repressed by JunB (Fig. 20) (29, 146). In contrast to this, JunB promotes production of 
effector cytokine IL-4 and IL13 in Th2 cell (Fig. 13). The promoting activity of JunB 
in Th2 effector function, however, is context-dependent, as deletion of JunB does not 
change expression of IL-4 and IL-13 in OT-II cells activated by papain immunization 
(Fig. 16). In mice immunized with papain, cytokines other than IL-4, which I used in 
in-vitro Th2 differentiation, might induce IL-4 and IL-13 independently of JunB. JunB 
regulates IFN-γ probably through T-bet regulation, as deletion of JunB upregulates the 
expression of T-bet in Th1 (Fig. 20). On the other hand, JunB is not required for GATA3 
expression in Th2 in vitro (Fig. 13).  
AP-1 factors likely regulate T helper cell differentiation in a context-dependent 
manner. For example, BATF is not required for Th1 differentiation but promotes Th2 
differentiation (Table 5) (89, 90). Another AP-1 protein, c-Maf, does not regulate the 
expression of IFN-γ in Th1 but promotes the expression of IL-4 in Th2 (149). This 
context-dependent regulation of AP-1 proteins could be explained by the difference of 
opening chromatin profiles between Th1 and Th2 cells. It could also be caused by the 
flexibility of AP-1 proteins in interacting with a variety of transcription factors through 
their C-terminal domains. For instance, JunB may interact with a potential IFN-γ 
inhibitor in Th1 cells but interact with other transcription factors in promoting the 
expression of IL-4 and IL-13 in Th2 cells. The difference of JunB-mediated protein 
interactomes should be investigated in future studies. 
 
Part III. The role of JunB in differentiation, proliferation, and cell death 
During activation, CD4+ T cells undergo a rapid expansion in responding to both 
antigen and cytokine stimulation. Meanwhile, antigen stimulation also induces the 
apoptosis. Until the antigen is removed, the rate of cell proliferation should be faster 
than the rate of apoptosis. Any disturbance of this balance will result in premature death 
of CD4+ effector T cells. More importantly, the premature death could also have the 
secondary effects on the differentiation into CD4+ effector T cells. 
JunB inhibits the rate of apoptosis of CD4+ effector T cells by inhibiting Bim 
expression. On the other hand, JunB does not regulate cellular proliferation, as deletion 
of JunB does not alter any pathways related to cell proliferation (Fig. 21). However, to 
further confirm this, CFSE dilution assay should be performed at an earlier time point, 
e.g., 3 days post immunization, in OVA peptide/adjuvants immunization experiment. 
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This can help us to understand whether deletion of JunB do affect the proliferation of 
CD4+ effector T cells or not. 
Deletion of JunB upregulates the expression of Bim and subsequently increases 
the percentages of apoptotic cells in CD4+ effector T cells (Fig. 7) activated in vivo. The 
expression of Bim expression in Junb-deficient OT-II cells is 2-fold when compared to 
control OT-II cells. The difference of percentages of apoptotic cells between Junb-
deficient and control OT-II cells, however, is modest (Fig. 17). This suggests that 
although the expression of Bim was upregulated, the onset of apoptosis and the 
subsequent accumulation of apoptotic cells may require a longer time. Hence, to 
observe a more significant influence caused by JunB deletion in OT-II cells, it is 
necessary to examine the percentage the apoptotic cells between control and Junb-
deficient OT-II cells at a later time point. 
JunB deletion further promotes the differentiation of Th1 but impaired the effector 
functions of Th2 cells. We still do not know whether increased cell death in Junb-
deficient Th1/Th2 cells is related to this altered differentiation. I can address this by 
analyzing the effect of CRISPR-Cas9-mediated Bim knock out on Th differentiation in 
Junb-deficient CD4+ effector T cells. 
 
Part IV. Comparisons of roles between JunB and IRF4/BATF in Th1 and 
Th2 cells 
In this thesis, I demonstrate that JunB has both common and different roles during Th1 
and Th2 differentiation when compared to IRF4 and BATF. Similar as IRF4 and BATF, 
JunB also promotes cell survival of CD4+ effector T cells. I further reveal that JunB 
inhibits Bim expression in both Th1 and Th2 (Table 5) (120, 135). Moreover, deletion 
of JunB increased the expression of Thy1 that encodes CD90 – a surface protein 
expressed among all CD4+ effector T cell subsets. Previous studies have suggested that 
apoptosis is increased in CD4+ effector T cells when surface CD90 molecules are 
crosslinked with other proteins or anti-CD90 antibodies (150). Therefore, deletion of 
JunB not only initiates the apoptosis through upregulating Bim expression, but also 
increases the susceptibility to apoptosis in both Th1 and Th2 cells.  
The role of JunB in Th1 differentiation is opposite to IRF4. As discussed before, 
JunB may act as a repressor of Th1 differentiation. In contrast to this, IRF4 promotes 
Th1 differentiation through promoting the expression of T-bet and IFN-γ as well as 
enzymes required for glycolysis (Table 5) (74). 
JunB regulates more biological functions than IRF4 and BATF during Th2 
differentiation. Similar as IRF4 and BATF, JunB promotes the expression of Th2 
effector cytokines IL-4 and IL-13 (Fig. 13) (75, 80, 90). In addition, JunB regulates 
metabolic reprogramming in Th2 and the expression of Pgm2l1 – enzyme required for 
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glycolysis (Fig. 14). JunB also inhibits the expression of exhaustion marker Lag3 (Fig. 
20) (Table 5). However, the role of IRF4 and BATF among these regulations have not 
been reported yet. 
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Table 5. A detailed list of comparisons of role of JunB in Th1 and Th2 with IRF4 
and BATF  
 
Cell Types TFs Main functions (Key target genes) Reference 
In both Th1 
and Th2 
JunB Promotes cell survival through inhibiting expression of apoptosis-
related molecules such as Bim and CD90. 
This study 
IRF4 Promotes cell survival in CD4+ effector T cells. (119) 
BATF Promotes cell survival in CD4+ effector T cells through inhibiting 
apoptosis. 
(120) 
Th1 JunB Inhibits the expression of T-bet and IFN-γ, as well as other lineage-
specific genes such as Il12rb2, Eomes, and IL2ra.  
This study, 
(101) 
IRF4 Promotes glycolysis of Th1 (HK2, GLUT3). 
Promotes the expression of IFN-γ, TNF-α and T-bet. 
(74) 
BATF No specific role has been reported yet. (89, 90) 
Th2 JunB Promotes the cytokine production of Th2 (IL-4 and IL-13). 
Promotes glycolysis of Th2 (PGM2L1). 
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Part V. Improvement of cell culturing conditions 
In in vitro differentiation experiments, the percentages of living cells of control (Junbfl/fl) 
CD4+ T cells is 13%, 60% and 50% when cultured under Th0-, Th1- and Th2-polaring 
conditions for 96h, respectively (Fig. 11A). These results suggest that the culturing 
conditions are not suitable for long-term survival of cells, especially under Th0-
polarizing conditions. It may be due to the differences of cytokine compositions 
between Th0- and Th1/2-polarizing conditions. The only cytokine present in Th0 
conditions is IL-2. However, in addition to IL-2, IL-12 and IL-4 were added in Th1- 
and Th2-polarizing conditions, respectively. As both IL-12 and IL-4 can enhance the 
cell viability as well as stimulating proliferation (151, 152), the survival signal provided 
in Th0-polarizing conditions may not be comparable to that in Th1 and Th2 conditions. 
One of the solutions is to increase the amount of IL-2 in Th0 conditions, as IL-2 alone 
can also provide survival signals and stimulate cell proliferation (153). Moreover, to 
avoid the possible nutrients and cytokine depletion during long-term culturing, a 1:3 
split of cells could be conducted at an earlier time point, e.g., 48h, before the analysis 
of apoptotic cells.  
 
Part VI. Improvement of in vivo immunization assays for observing the role 
of JunB in CD4+ effector T cell under exhaustion or low TCR stimulation  
Previous studies have suggested that JunB is rapidly induced in activated CD4+ T cells 
once TCR is stimulated. In this study, I further suggested that JunB promotes cell 
survival in CD4+ effector T cells both in vivo and in vitro. Hence, JunB is required for 
maintaining cell survival since the early stage of CD4+ T cell differentiation. However, 
JunB may play roles in other stages of CD4+ T cell differentiation. For example, JunB 
might be a potential inhibitor in T cell exhaustion during Th2 differentiation, as JunB 
directly binds and represses the expression of exhaustion marker Lag3 in Th2 cells (Fig. 
19, 22). To explore this possibility, it is important to investigate whether JunB prevents 
T cell exhaustion in vivo. 
In OVA peptide/adjuvants immunization experiments, most of OT-II cells became 
activated (Fig. 15) and a large proportion of Junb-deficient OT-II underwent cell death 
at 5 days post immunization (Fig. 16). Since JunB is necessary for accumulation of 
antigen-primed T helper cells, the current CD4-cre-dependent JunB knockout model is 
not suitable to evaluate the role of JunB in the events following to the priming of naïve 
CD4+ T cells. Analysis of the effect of deletion of JunB in exhausted T cells using 
conditional knockout models with tamoxifen inducible Cre recombinase such as CD4-
creERT2 might address this question.  
It is also interesting to see the role of JunB in T helper cells activated with different 
strength of TCR signal. In this thesis, I used an OVA peptide that shows high affinity to 
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OT-II TCR. The role of JunB in T helper cells activated with weaker TCR signal should 
be addressed in the future.   
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Chapter 5: Future directions 
 
Part I. The requirement of Bim for increased apoptosis in Junb-deficient 
CD4+ T cells  
My data suggest that one of the critical roles of JunB in CD4+ T cells is to inhibit the 
expression of Bim. To further analyze the importance of JunB-dependent regulation of 
Bim expression, the effect of Bim knockout in Junb-deficient CD4+ T cell should be 
evaluated with CRISPR-CAS9-mediated gene deletion. In this experiment, naïve CD4+ 
T cells from Junbfl/flCd4cre (Junb-deficient) mice will be electroporated with Cas9 
proteins and guide RNA targeting Bcl2l11 (gBim). After 72h activation under in-vitro 
Th1-, Th2-, and Th17-polarizing conditions, I will examine whether knockout of Bim 
can increase cell survival.  
 
Part II. The molecular mechanism of action of JunB in control of Bim-
mediated apoptosis in various CD4+ effector T cells 
Abundance of the apoptosis inducer Bim should be strictly regulated to prevent 
premature apoptosis in activated CD4+ T cells. Previous studies showed that ligation of 
TCR and antigens decrease the expression of Bim mRNA (154, 155), suggesting that a 
TCR-induced repressor for Bim might exist in CD4+ T cell differentiation. My data 
suggest that JunB is a critical regulator of Bim-mediated apoptosis, as deletion of JunB 
increased cell death as well as upregulation of Bim both in vitro and in vivo (Fig. 11C, 
17C, 19). Furthermore, JunB colocalizes with BATF and IRF4 on Bcl2l11 locus, 
suggesting that JunB directly regulates expression of Bcl2l11 (Fig. 22). 
JunB might regulate the expression of Bim through facilitating the binding of 
BATF and IRF4 to Bcl2l11 locus. Previous studies demonstrated that BATF and IRF4 
are potential repressors of Bim, as deletion of BATF and IRF4 upregulated expression 
of Bcl2l11 in activated T cells (66, 113). Mouse Bcl2l11 locus contains several 
conserved noncoding sequences (CNS) (Fig. 27), one of which starts at 9 kb upstream 
of the transcription starting site of Bcl2l11 (CNS-9, Fig. 26). My ChIP-Seq analysis 
demonstrated that JunB colocalized with BATF and IRF4 only at CNS-9 in Bcl2l11 
locus, suggesting that CNS-9 might be an important cis-regulatory element for JunB to 
regulate Bim-induced apoptosis during CD4+ T cell differentiation.  
Furthermore, the complex formed by JunB, BATF and IRF4 might also compete 
with the known Bim activators such as Forkhead box O3A (Foxo3A) to inhibit Bcl2l11 
expression (156). I searched Foxo3A-binding motif across the entire mouse genome 
and identified several genomic regions containing potential binding sites for Foxo3A 
on Bcl2l11 locus (Fig. 27). Among them, one Foxo3A binding site also locates within 
CNS-9 and are only 485 bp to the center regions of the JunB/BATF/IRF4-colocalizing 
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peaks (Fig. 27), suggesting a potential competition in DNA bindings between JunB-
BATF/IRF4 complex and Foxo3A proteins. 
To investigate whether the binding to CNS-9 region of BATF, IRF4 and Foxa3A 
is JunB-dependent, ChIP-PCR assay will be performed between Junb-deficient CD4+ 
T cells and controls cells with antibodies to BATF, IRF4 and Foxa3A. In this experiment, 
naïve CD4+ T cells from Junbfl/flCd4cre (Junb-deficient) and Junbfl/fl (control) mice will 
be activated under Th1-, Th2-, and Th17-polarizing conditions. After 72 h, chromatins 
will be collected and real time PCR assay will be performed to reveal whether Junb-
deficient CD4+ T cells exhibit altered bindings of BATF, IRF4, and Foxa3A at the CNS-
9 of Bcl2l11 locus.  
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Fig. 27. JunB-mediated DNA binding of other transcription factors on Bcl2l11 
locus.  
Schematic of JunB-binding motif, Foxa3A-binding motif, ChIP-seq peaks for JunB, 
BATF, and IRF4 in mouse Bcl2l11 locus, and conserved regions between mouse and 
human Bcl2l11 locus. JunB- and Foxo3A-binding motifs were identified through 
scanning the motif sequence across the entire mouse genome (ver. mm10). A consensus 
JunB ChIP-seq peak dataset was obtained from the union of JunB ChIP-seq data for 
Th1 cells and Th17 subsets (GSE86535). Conserved regions between mouse and human 
Bcl2l11 locus were identified by ECR browser by comparing mouse and human 
genome (ver. hg19 and ver. mm10) (157). Conserved regions that locate within 10 kbp 
upstream of transcription starting site of Bcl2l11 or within the gene body are labelled. 
The overlapping region between Foxa3A-binding site, JunB/BATF/IRF4-colocalizing 
peak, and CNS-9 region are highlighted. The Foxa3a-binding site is 485 bp from the 
center region of JunB/BATF/IRF4-colocalizing peak. CNS, conserved noncoding 
region; DPE, downstream promoter element. 
 
Part III. The role of JunB in aged CD4+ T cells 
Recent studies have suggested that the induction of Bim plays critical roles in 
eliminating functionally defective naïve CD4+ T cells from aged individuals (158). 
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Naïve CD4+ T cells from aged mice exhibit several functional defects during activation, 
including impaired proliferation, low cytokine production and poor abilities in helping 
B cell to produce antibodies (159–161). To ensure a healthy turnover of naïve CD4+ T 
cells in peripheral tissues, Bim is continuously induced and the expression level of Bim 
should be kept higher than its antagonist, Bcl-2. In naïve CD4+ T cells from young mice, 
the ratio of Bim to Bcl-2 is kept around 1.6 so that peripheral naive CD4+ T cells are 
relatively susceptible to apoptosis. However, the expression level of Bim decreases 
during aging and the ratio of Bim to Bcl-2 also decreases to below 1.0 (158). As a result, 
dysfunctional naïve CD4+ T cells accumulate in aged mice. Once activated, those CD4+ 
T cells exhibit defective IL-2 secretion and cannot efficiently help B cells to undergo 
class switch to IgG (158, 162).  
A small-scale study using six human subjects has demonstrated that the expression 
of main JunB partner, BATF, is increased in activated CD4+ T cells from aged 
individuals (older than 60 years) (163). Hence, it is interesting to investigate whether 
the induction of JunB is higher in CD4+ T cells in aged mice than those in young mice. 
To address this, aged (> 80 weeks) and young (<10 weeks) OT-II mice will be 
immunized with OVA323-339. Throughout the immunization, the expression levels of 
JunB of activated OT-II T cells from both aged and young mice will be analyzed. 
Meanwhile, whether the expression of Bim in activated OT-II cells from aged mice is 
lower than those from young mice will also be confirmed. 
If the results are in line with my hypothesis, then the next step is to investigate 
what factors cause the increased induction of JunB in CD4+ T cells of aged mice. One 
hypothesis is the increased plasma IL-6 level during aging. Our lab has revealed that in 
addition to antigen stimulation, pro-inflammatory cytokines such as IL-6 can also 
augment the expression of JunB in activated CD4+ T cells (100). Several clinical studies 
using human subjects also revealed that plasma IL-6 level is increased in older 
individuals compared to young individuals (164–167). To address this, plasma IL-6 
level will be determined in aged and young OT-II mice. We can further treat aged mice 
with anti-IL-6 antibodies to see if IL-6 depletion can decrease the level of JunB in CD4+ 
T cells of aged mice. Collectively, these studies will help us to understand the immune 
regulation mediated by IL-6-JunB-Bim axis during aging.  
 
Part IV. The role of JunB in cell-type-specific regulation 
My RNA-seq data identified many JunB target genes in a specific CD4+ effector T 
subset. Depending on cell-type-specific chromatin landscape JunB may bind and 
regulate different sets of genes in CD4+ effector T subsets. To investigate this possibility, 
the binding of JunB on its Th-subset-specific targets, including Eomes, Il12rb2, Il13, 
Il4ra and Il17a, will be examined by ChIP-PCR assay in cells cultured under Th1-, 
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Th2- and Th17-polarizing conditions. Furthermore, whether JunB facilitates BATF and 
IRF4 binding to these loci will be examined by ChIP-PCR assay in Junb-deficient CD4+ 
T cells with antibodies to BATF and IRF4.  
 
Part V. The role of JunB in chromatin remodeling 
BATF has been reported to regulate global chromatin structures during Th17 
differentiation (91). As the major BATF-interacting partner, JunB may also possess 
similar chromatin remodeling activities. To address this, the global chromatin 
accessibility between Junb-deficient and control cells, activated under Th1-, Th2-, and 
Th17-polarizing conditions, will be examined by using Assay for Transposase-
Accessible Chromatin sequencing (ATAC-seq) (168). The differential ATAC-seq peaks 
will be overlapped with my RNA-seq data set to reveal whether JunB-mediated 
chromatin modeling affects gene expression in each Th subset. 
 
Part VI. The JunB-mediated protein interactome 
My study reveal that JunB potentially interacts with various family proteins to regulate 
gene expression (Fig. 25). Previous studies also demonstrated JunB likely interacts with 
BACH2 and c-Maf in regulating differentiation of CD8+ T and Th2 cells, respectively 
(169, 170). Thus, JunB-mediated protein interactomes might exist in regulating effector 
functions and differentiation of various CD4+ effector T cells. To decipher the JunB-
mediated protein interactomes, JunB-interacting proteins will be harvested from Th1, 
Th2, and Th17 cells by immunoprecipitation with anti-JunB antibodies. The harvested 
proteins will be crosslinked, digested, and further analyzed by proteomics method. We 
can adopt data-independent acquisition mass spectrometry (DIA MS) technique, which 
allows us to identify the JunB-interacting partners in a full mass to charge (m/z) range 
without being restricted to predefined peptides of interest (171, 172). Moreover, 
through introducing a synthesized peptide with known concentrations, we can further 
quantify the relative abundance of complexes formed by JunB and BACH2, c-Maf and 
BATF in each CD4+ T cell effector subsets. 
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